



Edison Healthcare Insight

September 2018

Maxim Jacobs



Max joined Edison's healthcare team in December 2014. Prior to this he worked as a senior analyst at Guidepoint Global. Max has also previously worked as a senior analyst at Ridgemark Capital, a sector head at Broadfin Capital and as a senior analyst at Mehta Partners. He is a CFA charter holder.

Dr Nathaniel Calloway



Nathaniel Calloway joined the healthcare team in December 2015. Before Edison, he performed healthcare investment research for a fund at Bishop Rosen and for Wainscott Capital Partners. Prior to his role as an analyst he performed molecular neuroscience research at Cornell Medical School and holds a PhD in chemistry from Cornell. He has published eight scientific papers on topics ranging from physical chemistry to immunology, and he has been recognised as an American Heart Association fellow and an American Chemical Society Medicinal Chemistry fellow.

Pooya Hemami



Pooya is a licensed optometrist with over five years of experience in life sciences equity research. Prior to joining Edison, he covered the Canadian healthcare sector as a research analyst at Desjardins Capital Markets. He holds a doctor of optometry degree from the University of Montreal, and an MBA (finance concentration) from McGill University. He received his CFA charter in 2011.

Dr John Savin



John is an analyst working on biotech, pharma, medical device and diagnostics companies. As founder CEO of Physiomics, he devised the strategy, raised funds and took the company to AIM in 2004. At Greig Middleton, John was director in charge of the pharma and biotech analyst team and worked with corporate finance on fund-raising, IPOs and corporate restructuring. He has an industry background in sales and marketing with GE Healthcare and AstraZeneca and is a co-author on a number of scientific publications.

Juan Pedro Serrate



Juan joined Edison's Healthcare team in April 2016. A veterinarian by training, he has held business positions in the healthcare sector over the past 12 years. Juan has collaborated with independent equity research firms, specialising in fundamental analysis and valuations. For more than six years, he co-managed a seed capital fund in Spain that invested in biotech start-ups and projects. Earlier in his career, he was a research fellow at the Yale University School of Medicine. He has a Master's degree in biotechnology, as well as an MBA from IESE Business School.

Dr Dennis Hulme



Dennis joined Edison in December 2014. Prior to this he worked as an analyst at BBY Stockbrokers and as a research scientist at CSIRO. Dennis was ranked number two healthcare stock picker in the 2010 Starmine Analyst Awards and has a PhD in veterinary sciences.

Dr Jonas Pecilius




Jonas joined Edison in November 2015. He is a qualified medical doctor with several years of clinical practice. He then moved into equity research as a healthcare analyst at Norne Securities, focused on Norwegian companies, and received two StarMine awards for stock picking in 2013. Most recently, he worked for a London-based life sciences venture capital company before completing his MBA degree.

Dr Susie Jana



Susie joined the team in September 2015 and has 16 years' experience in the healthcare sector. She is a qualified medical doctor, having studied medicine at UCL. She also holds an intercalated BSc in psychology. After a few years working as a junior doctor in the NHS, Susie joined the investment banking industry for six years on the sell-side covering biotechnology stocks, then mid- to large-cap pharmaceuticals at Société Générale. Most recently she worked as a buy-side analyst, covering European biotech, pharma and medtech stocks at F&C Investments for five years.

Dr Andy Smith



Andy joined the Healthcare team at Edison in November 2017 after a period as a senior principal in ICON's Pricing & Market Access consultancy. Prior to ICON he was chief investment officer at Mann Bioinvest and managed healthcare and biotech funds at AXA Framlington, SV Life Sciences, Schroders and 3i Group. Andy is a scientist by training and completed his PhD with Glaxochem after working for ICI and in the NHS. Between working as a lecturer at Guy's Medical School, he worked in R&D management at SmithKline Beecham, before moving to the Strategic Product Development group in SB Pharmaceuticals to be a global product manager. Andy also has an MBA from the University of Greenwich and teaches the finance module on the Master's in Bioscience Enterprise course at the University of Cambridge.

Dr Daniel Wilkinson



Daniel joined Edison's Healthcare team in January 2016. He spent four years at Imperial College London, where he undertook both a Master's in Chemical Biology of Health & Disease and a PhD in Biosensors and Biotechnology in Diabetes. Before this he worked at eTect, a spin-out company from the University of Leeds that was focused on biosensor technology. He is currently studying for the Investment Management Certificate (IMC).

Alice Nettleton



Alice joined Edison's Healthcare team in November 2017. Previously, she worked as a business analyst at PharmaVentures on a variety of consulting projects relating to life science transactions. Alice holds a BSc in Biomedical Sciences from King's College London and an MSc in Business Creation and Innovation in Biomedicine from Gothenburg University, and while studying has completed two internships at IP Pragmatics.

Briana Warschun



Briana received her Master of Science in Biomedical Engineering from Brown University in May 2017. Before that, she received a BS in Biomedical Engineering with a minor in Biophysics from George Washington University. While pursuing her education, Briana gained work experience through internships at the medtech behemoth C.R. Bard as well as at the healthcare consulting firm The Advisory Board Company.

Contents

Company profiles	3
Company coverage	38

Prices at 14 September 2018

Published 21 September 2018

Welcome to the September edition of the Edison Healthcare Insight. In this edition we have profiled 69 of our healthcare companies under coverage.

Readers wishing more detail should visit our website, where reports are freely available for download (www.edisongroup.com). All profit and earnings figures shown are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison is a registered investment adviser regulated by the state of New York.

We welcome any [comments/suggestions](#) our readers may have.

Neil Shah & Maxim Jacobs

Healthcare Research

Company profiles

Prices at 14 September

US\$/£ exchange rate: 0.7648

€/£ exchange rate: 0.8913

C\$/£ exchange rate: 0.5881

A\$/£ exchange rate: 0.5499

NZ\$/£ exchange rate: 0.5018

SEK/£ exchange rate: 0.0853

DKK/£ exchange rate: 0.1195

NOK/£ exchange rate: 0.0928

JPY/£ exchange rate: 0.0069

NIS/£ exchange rate: 0.2100

CHF/£ exchange rate: 0.7899

Sector: Pharma & healthcare

Price: €3.70
Market cap: €113m
Market: FRA

Share price graph (€)



Company description

4SC is a Munich-based cancer biopharmaceutical company. Resminostat (HDAC inhibitor) is the lead candidate for CTCL (pivotal study started in Q416). It has a second compound, domatinostat (formerly 4SC-202; Phase II) and a preclinical asset, 4SC-208. 4SC has several partners including Yakult Honsha for resminostat in Japan.

Price performance

%	1m	3m	12m
Actual	(7.3)	(25.9)	(21.8)
Relative*	(4.9)	(20.7)	(18.6)

* % Relative to local index

Analyst

Dr Jonas Peciulis

4SC (VSC)

INVESTMENT SUMMARY

4SC's two lead assets are Resminostat (a broad-spectrum HDAC inhibitor) and Domatinostat (4SC-202; HDAC Class I specific inhibitor). Resminostat is uniquely positioned as a maintenance therapy to make remissions more durable for patients with advanced CTCL, who have achieved remission with systemic therapy. Enrolment is on track to reach 100 patients at the end of 2018 (4SC recruiting in Europe, Partner Yakult recruiting in Japan) and top-line data are expected in late 2019. Yakult has also initiated its own Phase II study for resminostat in biliary tract cancer in combination with S-1 chemotherapy. Domatinostat is being studied in Phase Ib/II SENSITIZE study in combination with pembrolizumab in melanoma. The first patient has recently been enrolled in the second dose cohort and top-line data are expected in H119. A second Phase II study EMERGE in GI cancer is expected to start in H218. 4SC-208 (downstream Hedgehog signalling pathway inhibitor) is the third asset expected to enter clinical development in 2019.

INDUSTRY OUTLOOK


Resminostat could become the first HDAC inhibitor to gain EU approval for CTCL (vs two HDACs approved in the US), but more importantly the maintenance treatment indication would be unique, potentially offering a competitive edge in Europe and the US.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	2.1	(10.9)	(10.9)	(54.17)	N/A	N/A
2017	4.2	(9.8)	(10.0)	(40.58)	N/A	N/A
2018e	4.7	(17.5)	(17.6)	(57.39)	N/A	N/A
2019e	3.1	(19.1)	(19.2)	(62.58)	N/A	N/A

Sector: Pharma & healthcare

Price: €3.83
Market cap: €203m
Market: Euronext Brussels

Share price graph (€)



Company description

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Its main product, BARHEMSYS, is for the treatment of PONV and is forecast to launch in 2019.

Price performance

%	1m	3m	12m
Actual	21.2	14.0	N/A
Relative*	24.8	17.7	N/A

* % Relative to local index

Analyst

Dr Susie Jana

Acacia Pharma (ACPH)

INVESTMENT SUMMARY

Acacia Pharma is focused on bringing antiemetic drugs to the US hospital setting for unmet needs in post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). We expect FDA approval of Acacia's lead product, BARHEMSYS (repurposed amisulpride), for the management of PONV by its 5 October 2018 PDUFA date. In the near term, Acacia will concentrate on the US commercial opportunity by expanding its sales and marketing infrastructure. We anticipate US launch of BARHEMSYS in Q219 for PONV 'rescue treatment' and expect broadening of use for PONV prophylaxis in subsequent years.

INDUSTRY OUTLOOK

Inadequately treated PONV leads to prolonged stay in post-anaesthesia care unit (PACU) recovery rooms. BARHEMSYS use could reduce patient hospitalisation time and the associated costs.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	0.0	(14.4)	(16.3)	(506.45)	N/A	N/A
2017	0.0	(3.0)	(6.5)	(231.59)	N/A	N/A
2018e	0.0	(19.6)	(20.3)	(36.39)	N/A	N/A
2019e	2.7	(43.0)	(45.6)	(82.03)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK7.36
Market cap: SEK169m
Market NASDAQ OMX First North

Share price graph (SEK)

Company description

Acarix, a Swedish company, sells the CE-marked CADScor to enable about half of the patients to be ruled out from further, expensive testing. Private sales in Germany have started. Full EU sales may start in late 2019. US sales might start from 2022.

Price performance

%	1m	3m	12m
Actual	26.5	(10.2)	(61.3)
Relative*	25.5	(13.4)	(63.4)

* % Relative to local index

Analyst

Dr John Savin

Acarix (ACARIX)

INVESTMENT SUMMARY

Acarix's H1 results show steady sales with eight systems and 900 disposable patches sold to June. This generated H1 revenues of SEK465k with gross profit of SEK349k, at a 75% margin. We now expect sales of just over SEK1m for the full year 2018 before hoped-for German reimbursement in 2019. A new commercial officer, Per Persson, has joined. We do not expect a US launch before 2022 and we assume a US trial starts in 2019. Additional clinical studies are ongoing. Sales in Austria have started.

INDUSTRY OUTLOOK

CADScor helps doctors to identify cardiac patients who probably require no further risky invasive clinical testing. The Dan-NICAD II study will enrol 2,000 patients with suspected stable coronary artery disease to add data, evaluate the test in patients aged 30–39 and aid acceptance of CADScor among key opinion leaders. The 'Seismo' study with 200 patients aims to explore the use of CADScor for the early diagnosis of heart failure.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	N/A	(26.8)	(26.8)	(183.01)	N/A	N/A
2017	0.6	(29.2)	(30.7)	(129.31)	N/A	N/A
2018e	1.1	(31.4)	(33.7)	(146.26)	N/A	N/A
2019e	3.8	(57.3)	(59.8)	(259.68)	N/A	N/A

Sector: Pharma & healthcare

Price: NZ\$2.20
Market cap: NZ\$214m
Market NZSX

Share price graph (NZ\$)

Company description

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company's product portfolio includes prescription and over-the-counter drugs to treat a range of conditions and a proprietary nebuliser.

Price performance

%	1m	3m	12m
Actual	(6.4)	(8.7)	(12.0)
Relative*	(8.9)	(10.8)	(22.8)

* % Relative to local index

Analyst

Maxim Jacobs

AFT Pharmaceuticals (AFT)

INVESTMENT SUMMARY

AFT Pharmaceuticals is a New Zealand-based speciality pharmaceutical company that currently sells 130 prescription speciality generics and OTC products through its own sales force in New Zealand, Australia and South-East Asia and has been expanding its geographic footprint. Maxigesic, its combination acetaminophen/ibuprofen product that is addressing a \$10.4b market, is currently sold and launched in 10 countries and distribution agreements are in place in a total of 125. Additionally, AFT recently reported positive results from a pivotal trial for Maxigesic IV. AFT is also developing a handheld device called SURF Nebuliser, which is able to deliver therapies intranasally, with a main focus on the \$3 billion conscious sedation market.

INDUSTRY OUTLOOK

AFT is a multi product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offers them a competitive advantage in a fragmented industry.

Y/E Mar	Revenue (NZ\$m)	EBITDA (NZ\$m)	PBT (NZ\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	69.2	(15.1)	(18.5)	(19.12)	N/A	N/A
2018	80.1	(10.5)	(12.9)	(13.30)	N/A	N/A
2019e	99.6	1.9	0.0	4.56	48.2	N/A
2020e	120.7	11.7	9.9	10.13	21.7	23.1

Sector: Pharma & healthcare

Price: NIS1.20
Market cap: NIS86m
Market: TASE

Share price graph (NIS)

Company description

Allium Medical Solutions is a company focused on developing and marketing minimally invasive devices in various areas: cardiovascular, metabolic, genitourinary and gastrointestinal. The company has three selling product lines: Allium Stents, IBI (EndoFast) and Gardia Medical.

Price performance

%	1m	3m	12m
Actual	9.4	(9.8)	25.1
Relative*	5.5	(14.3)	9.7

* % Relative to local index

Analyst

Juan Pedro Serrate

Allium Medical (ALMD)

INVESTMENT SUMMARY

Allium Medical Solutions is a company focused on developing and marketing minimally invasive devices in the cardiovascular, metabolic, genitourinary and gastrointestinal areas. The company has three selling product lines: Allium Stents, IBI (EndoFast) and Gardia Medical. Peripheral stents and EndoFast urogynecology devices generate the bulk of revenues (92% of NIS7.7m in 2017). Allium has achieved revenue CAGR of 20% in 2011-17. The investment case rests on its ability to execute on its ambitious growth strategy, with revenues expanding at a double-digit rate as the company continues to gain market share in established and new regions. We estimate that cash, equivalents and short-term deposits of c NIS16.6m at end-H118 provide runway until 2019.

INDUSTRY OUTLOOK

We expect Allium's growth to accelerate in the medium term, resulting in 2018-20e revenue CAGR of 43%. Allium has two devices in development: Allevetix, in a clinical trial for diabetes and obesity; and TruLeaf, a mitral valve replacement device in preclinical studies. Gardia's Wirion device has been approved by the FDA, becoming the only embolic protection system for all atherectomy procedures. Stents have been approved in China. Stents and EndoFast have been approved in Russia.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2016	7.4	(20.4)	(22.0)	(0.49)	N/A	N/A
2017	7.7	(20.8)	(21.4)	(0.37)	N/A	N/A
2018e	14.0	(13.2)	(13.7)	(0.19)	N/A	N/A
2019e	21.0	(9.0)	(9.6)	(0.13)	N/A	N/A

Sector: Pharma & healthcare

Price: 46.5p
Market cap: £66m
Market: AIM

Share price graph (p)

Company description

Angle is a world leading liquid biopsy company with a potentially disruptive platform technology. The patented Parsortix cell separation platform can harvest circulating tumour cells and other very rare cells from a blood sample for downstream analysis.

Price performance

%	1m	3m	12m
Actual	(8.8)	(17.7)	34.8
Relative*	(4.9)	(13.1)	35.4

* % Relative to local index

Analyst

Dr Jonas Peculis

Angle (AGL)

INVESTMENT SUMMARY

Angle's Parsortix cell separation platform is used to detect and harvest circulating tumour cells from blood. CTCs provide the complete picture since viable, intact CTCs can be used for DNA, RNA and protein analysis as well as culturing and xenograft models. Angle acquired Ziplex platform of Axela, a multiplex solution providing enhanced analysis of protein, DNA and RNA. This will allow Angle to offer a "sample to answer" product to its clients. A key catalyst in the near term is the completion of the FDA clinical studies in breast cancer expected in H218 and a potential subsequent submission to the FDA. The company reported results from its two studies (n=200 each) for triaging women with ovarian masses before surgery. Reported ROC-AUC was high at 95.1% (assay combines the expression levels of 9 different genes and 4 serum markers). Angle has existing collaboration agreements with three multinationals (Qiagen, Philips and Abbott) indicating growing interest in CTCs from large players. We are updating our estimates.

INDUSTRY OUTLOOK

The precision medicine approach is an initiative aiming to improve treatment efficacy by tailoring the treatment to the patient and their disease with liquid biopsy being one of the key enabling tools.

Y/E Apr	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	0.4	(4.9)	(5.0)	(7.97)	N/A	N/A
2017	0.5	(6.7)	(6.9)	(8.03)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €3.21
Market cap: €56m
Market: Euronext Brussels

Share price graph (€)



Company description

ASIT biotech is a clinical-stage company focused on developing therapies for allergies. It uses its proprietary ASIT+ technology platform to develop products containing highly purified allergen fragments in an adjuvant-free formulation, selected to be safe while maintaining the capacity to stimulate the immune system.

Price performance

%	1m	3m	12m
Actual	(13.0)	(18.7)	(27.0)
Relative*	(10.4)	(16.1)	(21.2)

* % Relative to local index

Analyst

Andy Smith

ASIT biotech (ASIT)

INVESTMENT SUMMARY

ASIT Biotech's ASIT+ allergy immunotherapy (AIT) platform has generated a Phase III drug for the prevention of grass pollen allergy and earlier-stage programs in house dust mite (hdm-ASIT+) and in peanut allergies. Unlike most other AITs (subcutaneous or sublingual), ASIT's products only require four injections prior to the allergy season. The second Phase III study for gp-ASIT+ starts recruiting at the end of Q418 and results are expected after the pollen season of 2019. We expect ASIT Biotech to self-market its products in Europe and license-out rights in for the US and China. ASIT recently raised money to fully-fund its clinical programs.

INDUSTRY OUTLOOK


Although grass pollen and house dust mite allergies are not life-threatening in most cases, they result in a significant symptom burden for affected patients. With a safe and effective four-dose regimen, ASIT could expect some usage in the less-severe segment where currently a regimen of many doses does not balance the risk-benefit.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(12.3)	(12.3)	(110.00)	N/A	N/A
2017	0.0	(12.0)	(12.0)	(93.60)	N/A	N/A
2018e	0.0	(11.9)	(11.8)	(76.17)	N/A	N/A
2019e	0.0	(12.3)	(12.2)	(74.44)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$7.66
Market cap: US\$246m
Market: Taiwan

Share price graph (US\$)



Company description

ASLAN Pharmaceuticals is a Singapore based drug developer targeting Asia prevalent diseases. Varlitinib is in pivotal clinical trials for biliary tract cancer and gastric cancer and ASLAN003 will be advanced to Phase II trials for acute myeloid leukaemia.

Price performance

%	1m	3m	12m
Actual	(4.3)	(15.0)	N/A
Relative*	(6.4)	(18.6)	N/A

* % Relative to local index

Analyst

Dr Nathaniel Calloway

ASLAN Pharmaceuticals (ASLN)

INVESTMENT SUMMARY

ASLAN is a pharmaceutical company focused on in-licensing early-stage assets for diseases with a high prevalence in Asia that are orphans in the West. This allows the company to quickly progress these assets through clinical trials in Asia. The goal then is to out-license rights to the EU and Japan while commercialising in the US and other Asian geographies. The company's lead programme is varlitinib, a pan-HER inhibitor in a pivotal trial for biliary tract cancer (BTC) and Phase II/III for gastric cancer (GC). Initial readouts for these trials are planned for 2018. It's also testing ASLAN003, an inhibitor of dihydroorotate dehydrogenase, in Phase II for acute myeloid leukaemia, and ASLAN004, in Phase I for atopic dermatitis.

INDUSTRY OUTLOOK

ASLAN's Asia focused development strategy allows it to address certain indications that have otherwise proven difficult to develop drugs for, such as biliary tract cancer, which has no approved targeted therapies.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	11.5	(7.2)	(7.6)	(7.26)	N/A	N/A
2017	0.0	(37.8)	(38.8)	(31.16)	N/A	N/A
2018e	0.0	(40.5)	(40.8)	(26.49)	N/A	N/A
2019e	0.0	(60.7)	(61.1)	(35.96)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.80
Market cap: US\$9m
Market: NASDAQ

Share price graph (US\$)

Company description

Based in Seattle, WA, Atossa Genetics is focused on the development of locally administered pharmaceuticals for the treatment of pre-cancer and early-stage breast cancer. Lead candidate afimoxigene topical gel is expected to start a Phase II study in 2016 in breast hyperplasia or DCIS.

Price performance

%	1m	3m	12m
Actual	(20.4)	(30.8)	(78.4)
Relative*	(22.6)	(33.8)	(81.4)

* % Relative to local index

Analyst

Pooya Hemami

Atossa Genetics (ATOS)

INVESTMENT SUMMARY

Atossa is advancing endoxifen, a metabolite of tamoxifen, as a topical treatment for high mammographic breast density (MBD), a condition associated with higher cancer risk. Atossa is also developing oral endoxifen as a potential treatment for breast cancer patients refractory to tamoxifen. About 20-25% of the 1.0m women taking tamoxifen worldwide develop resistance to it, and have an increased risk for cancer recurrence. The firm reported positive Phase I data for both formulations, including results showing that patients obtain "steady state" serum endoxifen levels after about 7 days of daily oral dosing.

INDUSTRY OUTLOOK

Atossa started Phase II trials for oral and topical endoxifen, and expects to complete enrollment for the topical study by YE18. The firm recently reported positive Phase I topical endoxifen safety data in men and is planning to start a Phase II study in men with gynecomastia. It also started preclinical studies with its IDMC to explore potential use in immunotherapy. Atossa raised \$13.4m gross (\$12.1m net) through a Q218 rights offering. It reported \$15.2m net cash on 30 June 2018, which we believe can sustain operations until early 2020.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(6.9)	(7.3)	(2951.72)	N/A	N/A
2017	0.0	(7.1)	(7.2)	(1000.81)	N/A	N/A
2018e	0.0	(11.4)	(11.4)	(429.43)	N/A	N/A
2019e	0.0	(7.0)	(7.0)	(257.02)	N/A	N/A

Sector: Pharma & healthcare

Price: CHF61.60
Market cap: CHF732m
Market: Swiss Stock Exchange

Share price graph (CHF)

Company description

Basilea focuses on anti-infectives and oncology. Lead products are Cresemba (an antifungal), which is approved in the US and Europe, and Zevtera (an anti-MRSA broad-spectrum antibiotic), approved in many European and non-European countries for pneumonia.

Price performance

%	1m	3m	12m
Actual	(10.1)	(12.4)	(22.8)
Relative*	(9.7)	(15.6)	(22.0)

* % Relative to local index

Analyst

Dr Susie Jana

Basilea Pharmaceutica (BSLN)

INVESTMENT SUMMARY

Basilea has two approved hospital-based products: Cresemba (severe mold infections) and Zevtera (bacterial infections). During H118 Zevtera initiated the US Phase III registration trials in ABSSSI and SAB. Multiple licensing/distribution agreements announced in 2017 for marketed assets Cresemba and Zevtera should drive top-line growth faster than we had expected. Major deals with Pfizer include Cresemba in Europe (ex Nordics), Russia, Turkey, Israel, China and Asia-Pacific. Basilea's oncology pipeline focuses on drugs that target resistance to current cancer therapies. BAL101553 (Phase IIA in glioblastoma and ovarian cancer) and BAL3833 (phase I in solid tumours). Basilea has in-licensed ARQ 087 (derazantinib) from ArQule, a pan FGFR tyrosine kinase inhibitor in Phase II registration study for intrahepatic cholangiocarcinoma and Phase I/II development for solid tumours.

INDUSTRY OUTLOOK

There is an increasing need for novel antimicrobial agents with efficacy against resistant strains of bacteria (eg MRSA) and/or improved side effect profiles. Hence the opportunities for Zevtera and Cresemba could be significant.

Y/E Dec	Revenue (CHFm)	EBITDA (CHFm)	PBT (CHFm)	EPS (fd) (CHFc)	P/E (x)	P/CF (x)
2016	66.0	(41.6)	(50.9)	(505.74)	N/A	N/A
2017	101.5	(12.2)	(18.9)	(178.36)	N/A	35.0
2018e	124.0	(21.9)	(29.6)	(274.34)	N/A	N/A
2019e	137.3	(18.8)	(26.7)	(247.83)	N/A	N/A

Sector: Pharma & healthcare

Price: NIS14.34
Market cap: NIS65m
Market: TASE

Share price graph (NIS)



Company description

Based in Israel, BioLight is an emerging ophthalmic company focused on the development and commercialisation of products and product candidates that address ocular conditions. Lead products IOPTiMate and VS-101 are directed towards the treatment of glaucoma.

Price performance

%	1m	3m	12m
Actual	24.0	7.2	(1.4)
Relative*	19.6	1.8	(13.5)

* % Relative to local index

Analyst

Pooya Hemami

BioLight Life Sciences (BOLT)

INVESTMENT SUMMARY

BioLight Life Sciences is developing Eye-D VS-101, an extended-dose latanoprost drug implant designed to treat glaucoma (and had positive data in a Phase I/IIa trial) and TeaRx, a dry-eye syndrome diagnostic test. VS-101 can be helpful for the 20-60% of glaucoma patients who do not comply with daily eye-drop therapy.

INDUSTRY OUTLOOK

BioLight's IOPTima subsidiary signed an agreement in Q417 to be acquired by Chengdu Kanghong Pharma in a four-stage transaction. The first stage was completed in Q118 and, if remaining conditions are met, the gross proceeds to BioLight for its stake should range between \$23m and \$27.5m (by mid-2021). BioLight reported NIS33.7m in net cash (consolidated) at 31 March 2018, but NIS29.6m of this was held at IOPTima, and the parent firm only held NIS1.6m. BioLight raised NIS11.4m in May 2018 through the issuance of 908,540 shares. We believe these proceeds should allow BioLight to fund its operations until at least H218, at which point we expect it to receive \$12m from the second stage of the IOPTima divestiture transaction.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2016	2.1	(20.2)	(26.3)	(5.37)	N/A	N/A
2017	1.2	(26.8)	(26.6)	(5.29)	N/A	N/A
2018e	0.9	(24.0)	(26.3)	(5.21)	N/A	N/A
2019e	0.9	(24.4)	(26.3)	(5.56)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.52
Market cap: A\$251m
Market: ASX

Share price graph (A\$)



Company description

Bionomics is a Australia based pharmaceutical company developing drugs to target ion channels to treat neuropsychiatric diseases and cancer.

Price performance

%	1m	3m	12m
Actual	11.8	(4.6)	10.6
Relative*	13.6	(6.2)	2.9

* % Relative to local index

Analyst

Dr Nathaniel Calloway

Bionomics (BNO)

INVESTMENT SUMMARY

Bionomics is a clinical-stage pharmaceutical company with two small molecule discovery platforms: ionX for ion channel targets and MultiCore chemistry for rapid candidate identification. The company is testing BNC210 in Phase IIb for post-traumatic stress disorder (PTSD) and Phase IIa for agitation. It also had a programme licensed to Merck in Phase I for royalties, and US\$506m in upfront and milestone payments.

INDUSTRY OUTLOOK

There are currently limited options for sufferers of PTSD, which does not respond to treatment as well as other anxiety centered disorders. BNC210 hopes to surmount this with its novel anxiolytic mechanism.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	18.6	(3.2)	(4.4)	(1.00)	N/A	N/A
2018	4.0	(22.5)	(24.4)	(4.84)	N/A	N/A
2019e	17.9	(17.7)	(19.3)	(3.65)	N/A	N/A
2020e	4.3	(28.4)	(32.5)	(5.86)	N/A	N/A

Sector: Pharma & healthcare

Price: DKK4.99
Market cap: DKK776m
Market NASDAQ OMX First North

Share price graph (DKK)

Company description

BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes a portfolio of products marketed for research use and The NGAL Test, which the company has submitted to the FDA for the prediction of acute kidney injury.

Price performance

%	1m	3m	12m
Actual	42.6	60.5	55.0
Relative*	43.4	57.4	57.1

* % Relative to local index

Analyst

Dr Nathaniel Calloway

BioPorto Diagnostics (BIOPOR)

INVESTMENT SUMMARY

BioPorto's lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The test has completed initial clinical trials and has been submitted for 510(k) approval with the FDA, with launch planned for early 2019. The NGAL test is commercially available for research purposes in the US and has been CE marked in Europe. BioPorto also sells a series of other antibodies, ELISA kits and related biologics.

INDUSTRY OUTLOOK

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Y/E Dec	Revenue (DKKm)	EBITDA (DKKm)	PBT (DKKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2016	20.7	(22.6)	(22.4)	(156.7)	N/A	N/A
2017	25.2	(33.1)	(33.7)	(202.7)	N/A	N/A
2018e	29.6	(33.8)	(33.3)	(187.1)	N/A	N/A
2019e	52.7	(28.8)	(28.1)	(150.0)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK18.80
Market cap: SEK955m
Market OMX

Share price graph (SEK)

Company description

BONESUPPORT is an orthobiologics company that has commercialised three synthetic bone graft substitutes and has several other projects in R&D. The marketed products, CERAMENT BVF, CERAMENT G (gentamicin) and CERAMENT V (vancomycin), are intended to help orthopaedic surgeons manage bone voids and defects after injuries or diseases affecting bones.

Price performance

%	1m	3m	12m
Actual	28.8	79.7	(17.9)
Relative*	27.8	73.5	(22.5)

* % Relative to local index

Analyst

Dr Jonas Peculis

BONESUPPORT (BONEX)

INVESTMENT SUMMARY

BONESUPPORT's investment case rests on three strategic pillars: effective commercial organisation, products backed by clinical data and R&D innovation. The company is commercialising synthetic bone graft substitutes and invests in R&D to support continued development of innovative products that command premium pricing and differentiate them in a competitive market. Following recent issues with the exclusive, long-standing distributor in the US, BONESUPPORT terminated the agreement and US sales are expected to recover via an independent distributor network and a more hands-on approach to growing sales. The company has recently signed agreements with MTF Biologics and Collagen Matrix so that it can grow its product offering sold through its US platform and plans to drive sales in Trauma. After a successful IPO in June 2017 raising SEK520m, the company is well funded.

INDUSTRY OUTLOOK

Innovation is one of the key strategic directions for BONESUPPORT in order to differentiate its products from competitors offering commodity-like bone graft substitutes. The company has gathered data and is undertaking clinical trials to support the claims of its marketed products.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	104.6	(87.4)	(108.4)	(422.06)	N/A	N/A
2017	129.3	(97.9)	(126.7)	(320.78)	N/A	N/A
2018e	113.8	(165.9)	(164.0)	(326.48)	N/A	N/A
2019e	210.9	(129.7)	(128.6)	(253.68)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK19.50
Market cap: SEK1291m
Market NASDAQ OMX First North

Share price graph (SEK)

Company description

Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm First North in 2015. It is developing two antibodies against IL1RAP, CAN04 and CANxx. CAN04 is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer.

Price performance

%	1m	3m	12m
Actual	6.3	30.9	197.2
Relative*	5.5	26.3	180.7

* % Relative to local index

Analyst

Dr Jonas Pecilius

Cantargia (CANT)

INVESTMENT SUMMARY

Cantargia is developing two antibodies against IL1RAP: Nidanilimab (CAN04) and CANxx. Nidanilimab is currently being studied in a Phase I/II CANFOUR trial where the Phase I part is focusing on several solid tumours, and the Phase II part will focus on NSCLC and pancreatic cancer. Nidanilimab was well tolerated in the first 15 patients, and final safety data are expected in Q418. Nidanilimab has a dual mechanism of action: inhibition of IL-1 signaling and antibody-dependent cellular cytotoxicity (ADCC). Novartis is starting three Phase III trials in NSCLC with canakinumab (IL-1beta antibody) following some unexpected results from its six-year Phase III cardiovascular outcomes study in heart attack patients. Cantargia has recently up-listed to the Nasdaq Stockholm main market from Nasdaq Stockholm First North.

INDUSTRY OUTLOOK

Increasing the understanding of inflammation in malignant process now includes findings that cytokines are not only produced by the immune cells, but also cancer itself could produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent potentially promising class of targets in cancer management.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2016	0.0	(47.6)	(47.5)	(271.96)	N/A	N/A
2017	0.0	(60.0)	(60.3)	(186.00)	N/A	N/A
2018e	0.0	(85.8)	(83.3)	(147.34)	N/A	N/A
2019e	0.0	(93.8)	(93.5)	(141.19)	N/A	N/A

Sector: Pharma & healthcare

Price: €26.25
Market cap: €237m
Market Euronext Growth

Share price graph (€)

Company description

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

Price performance

%	1m	3m	12m
Actual	(2.6)	26.5	6.8
Relative*	(1.3)	29.2	4.2

* % Relative to local index

Analyst

Maxim Jacobs

Carmat (ALCAR)

INVESTMENT SUMMARY

Carmat is currently enrolling its 20-patient study for its artificial heart in France, Kazakhstan, the Czech Republic and Denmark. To date, ten patients have been implanted, with a 100% survival rate at one-month. Most notably, Carmat announced the first successful donor heart transplant of a TAH patient who was initially too sick to receive a donor heart. It also announced the certification of its new and more automated production facility, in Bois-d'Arcy, which will enable the production of up to 800 Carmat TAH units per year at full capacity.

INDUSTRY OUTLOOK

The Carmat artificial heart is being developed as a permanent replacement or destination therapy (DT) for chronic biventricular heart failure or acute myocardial infarction patients, who do not have access to a human donor heart. Despite the high EU and US prevalence of Stage IV heart failure (c 500,000 patients), the shortfall in donor hearts is such that only about 3,800 human heart transplants were performed in Europe and the US in 2013.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(19.4)	(20.6)	(381.3)	N/A	N/A
2016	0.3	(24.1)	(25.7)	(379.7)	N/A	N/A
2017e	0.0	(27.9)	(29.1)	(406.4)	N/A	N/A
2018e	0.0	(27.5)	(28.4)	(315.4)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$20.50
Market cap: US\$348m
Market: NASDAQ

Share price graph (US\$)

Company description

Cellular Biomedicine Group is a biotechnology company developing cell-based therapeutics with operations primarily in China. It has completed Phase II clinical trials of ReJoin, an autologous progenitor cell therapy for osteoarthritis, and it is developing a similar allogeneic product (AlloJoin). It has developed a CD19 CAR-T, which is currently in Phase I testing in China.

Price performance

%	1m	3m	12m
Actual	0.5	17.8	85.5
Relative*	(2.4)	12.6	59.6

* % Relative to local index

Analyst

Dr Nathaniel Calloway

Cellular Biomedicine Group (CBMG)

INVESTMENT SUMMARY

Cellular Biomedicine Group (CBMG) is a trans-Pacific cell therapy company developing products in China and the US. It has two ongoing Phase I clinical trials of CD19 chimeric antigen receptor T-cell (CAR-T) therapies for blood cancers (adult ALL and DLBCL) in China and recently received INDs from the CFDA for both indications. Data is expected around end-H118. Additionally, it is adapting its knee osteoarthritis (KOA) treatment ReJoin as an allogeneic product, AlloJoin, which recently completed Phase I testing.

INDUSTRY OUTLOOK

The company is focusing on CAR-T. The first CAR-T therapies were just recently approved in 2017 for the treatment of ALL and DLBCL, with developing ongoing in other hematologic malignancies such as multiple myeloma. Progress in the space has triggered significant M&A interest: Gilead bought Kite Pharma for \$12bn in August 2017, and Celgene has an outstanding tender offer for Juno Therapeutics at \$9bn.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	0.6	(15.7)	(18.1)	(134.30)	N/A	N/A
2017	0.3	(19.2)	(20.1)	(140.41)	N/A	N/A
2018e	0.0	(19.9)	(23.1)	(129.61)	N/A	N/A
2019e	0.0	(24.1)	(27.8)	(148.06)	N/A	N/A

Sector: Pharma & healthcare

Price: €23.76
Market cap: €284m
Market: Euronext Brussels

Share price graph (€)

Company description

Celyad is developing an innovative Natural Killer Receptor CAR T-cell therapy (CYAD-01). This focusses on AML and metastatic colorectal cancer. A comprehensive set of clinical studies is being initiated.

Price performance

%	1m	3m	12m
Actual	(6.4)	(4.6)	(47.0)
Relative*	(3.6)	(1.4)	(42.7)

* % Relative to local index

Analyst

Dr John Savin

Celyad (CYAD)

INVESTMENT SUMMARY

Celyad's first clinical trial design for its allogeneic NRK CAR T-cell therapy (CYAD-101) is an important milestone and is FDA agreed. The study mirrors the current colorectal SHRINK trial: a combination of autologous CYAD-01 therapy with FOLFOX chemotherapy. This gives Celyad the lead in a mass-market solid cancer, where allogeneic therapy is likely to be essential. Under a revised THINK protocol, a colorectal patient was treated with CAR preconditioning therapy before CYAD-01 dosing. Interim data from THINK are promised in late 2018, probably at ASH. Other studies are running or starting. The May placing gave Celyad a cash boost of €46.1m gross, making €62.4m on 30 June. The H118 operational cash outflow was €13.9m.

INDUSTRY OUTLOOK

CAR T-cell therapeutics remains a hot area for investment with increasing interest in the next stage of allogeneic products, where Celyad holds a key patent. Celyad remains in a key position in both AML and mCRC with a strong programme in solid tumours.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	8.5	(21.2)	(20.0)	(209.0)	N/A	N/A
2017	3.5	(22.3)	(26.8)	(279.0)	N/A	N/A
2018e	0.0	(26.5)	(27.3)	(243.0)	N/A	N/A
2019e	0.0	(27.8)	(28.5)	(238.0)	N/A	N/A

Sector: Pharma & healthcare

Price: NIS3.39
Market cap: NIS547m
Market: TASE

Share price graph (NIS)



Company description

Clal Biotechnology Industries is a healthcare investment company focused on investing in a variety of therapeutic, diagnostic, and medical device companies covering a full range of development phases from preclinical to post-market.

Price performance

%	1m	3m	12m
Actual	6.4	10.1	5.1
Relative*	2.6	4.6	(7.9)

* % Relative to local index

Analyst

Maxim Jacobs

Clal Biotechnology (CBI)

INVESTMENT SUMMARY

Clal Biotechnology (CBI) is a healthcare investment company with an extensive portfolio incorporating a diverse range of technologies, indications and stages of development. CBI holds direct investments in 10 companies (nine biotech and one medical device company), most importantly MediWound, a NASDAQ-listed wound care company and Gamida Cell, which is developing a universal bone marrow transplant (BMT) product. Also, Anchiano (formerly BioCancell) and Biokine have programs in Phase III or Phase III ready. 2018 and 2019 are expected to be very eventful years for CBI, with key data expected from several portfolio companies, including MediWound. In addition, NASDAQ listings are currently targeted for Gamida Cell and Anchiano. Neon recently went public in a \$100m NASDAQ IPO.

INDUSTRY OUTLOOK

CBI is invested in a variety of life science companies, including a wide and diverse range of technologies, indications and stages of development, all of which have high potential.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2016	30.5	(434.8)	(454.1)	(289.34)	N/A	N/A
2017	73.6	(103.3)	(54.2)	(15.02)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: NIS0.37
Market cap: NIS64m
Market: NASDAQ, TASE

Share price graph (NIS)



Company description

CollPlant is an Israel-based regenerative medicine company. It is focused on developing and commercializing tissue repair products with its plant-based technology, rhCollagen. It has two products on the market, VergenixSTR and Vergenix FG, and has received several orders for its 3D bioprinting product bioInk.

Price performance

%	1m	3m	12m
Actual	(3.9)	(17.7)	(15.6)
Relative*	(7.4)	(21.8)	(26.0)

* % Relative to local index

Analyst

Maxim Jacobs

CollPlant Holdings (CLGN)

INVESTMENT SUMMARY

CollPlant is an Israel-based regenerative medicine company. It is focused on developing and commercializing tissue repair products with its plant-based technology, rhCollagen. It has two products on the market, VergenixSTR and VergenixFG, and has received several orders for its 3D bioprinting product bioInk. It received its first order in September from a major biotechnology company, which subsequently reordered more product valued in the hundreds of thousands of dollars. The company intends to use the product to print organs for transplant. Additionally, CollPlant has received an order from a major medical device company in the order of multiple tens of thousands of dollars to develop a 3D printed orthopaedic implant.

INDUSTRY OUTLOOK


Orthobiologics and advanced wound care are substantial growing markets and are estimated to be worth \$6.7bn (according to GlobalData) and \$8.5bn (according to Smith & Nephew) respectively.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2016	0.3	(27.0)	(27.9)	(27.72)	N/A	N/A
2017	1.7	(19.7)	(20.9)	(15.68)	N/A	N/A
2018e	3.3	(20.3)	(21.3)	(11.86)	N/A	N/A
2019e	7.3	(18.1)	(19.6)	(10.40)	N/A	N/A

Sector: Pharma & healthcare

Price: €2.41
Market cap: €38m
Market: Euronext Growth

Share price graph (€)



Company description

Deinove is a biotech company that discovers, develops and manufactures compounds of industrial interest stemming from rare bacteria and intended for the health, nutrition and beauty markets.

Price performance

%	1m	3m	12m
Actual	(0.4)	(27.3)	19.3
Relative*	0.9	(25.7)	16.3

* % Relative to local index

Analyst

Dr Jonas Pecilius

Deinove (ALDEI)

INVESTMENT SUMMARY

FY18 is shaping up to be a pivotal year for Deinove. The company has already launched two products in its cosmetic division and has signed partnership agreements with Redx Pharma and Naicons to develop new antibiotics. Most significantly, Deinove announced the acquisition of Morphochem's clinical-stage antibiotic compound MCB3837, and recently raised €8.5m (via the issue of 3.15m shares at a price of €2.7 per share, resulting in dilution of 20.2%) to enable it to launch a Phase II clinical trial for the compound and finance its other activities. The funds raised are said to be sufficient to finance its operations over the next 12 months. As a result of contributing €2m to the capital increase, TVM Capital now holds 7.4% of Deinove. Our forecasts are under review.

INDUSTRY OUTLOOK

Environmentalism will underpin growth in green chemistry and the growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.8	(6.4)	(7.7)	(72.6)	N/A	N/A
2017	0.2	(8.5)	(9.7)	(67.7)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: 89.0p
Market cap: £39m
Market: AIM

Share price graph (p)



Company description

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobial agents that have unique properties to improve outcomes for patients. Destiny's first product, XF-73, is about to start a US Phase IIb clinical study.

Price performance

%	1m	3m	12m
Actual	(9.6)	(19.1)	(46.1)
Relative*	(5.8)	(14.6)	(45.8)

* % Relative to local index

Analyst

Andy Smith

Destiny Pharma (DEST)

INVESTMENT SUMMARY

Destiny Pharma is a virtual UK antimicrobial discovery company in Phase II clinical studies in the US. Destiny's XF series of antimicrobial agents are novel, rapidly bactericidal and not associated with bacterial resistance, which typically limits the use of other antimicrobial agents. This makes Destiny's lead product, XF-73, ideal for the prevention of post-operative infections, an indication in which no other drugs have been approved. We forecast Destiny's cash reach to at least 2020, with Phase IIb results for XF-73 available at the end of 2019.

INDUSTRY OUTLOOK

While there are valid commercial criticisms of antibiotic development, the growing problem of antimicrobial resistance is making non-dilutive and alternative funding methods available to make antimicrobial drug development easier on companies. In addition, resistance has not been observed against Destiny's agents and their new preventative indications make antibiotic stewardship less of an issue.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (fd) (p)	P/E (x)	P/CF (x)
2016	0.0	(1.3)	(1.5)	(3.94)	N/A	N/A
2017	0.0	(2.5)	(3.2)	(8.45)	N/A	N/A
2018e	0.0	(6.8)	(7.4)	(14.43)	N/A	N/A
2019e	0.5	(8.3)	(8.3)	(15.40)	N/A	N/A

Sector: Pharma & healthcare

Price: 7.5p
Market cap: £20m
Market: AIM

Share price graph (p)

Company description

e-Therapeutics is a UK-based drug discovery company that has developed a proprietary network-driven drug discovery platform that has generated pre-clinical licensing opportunities.

Price performance

%	1m	3m	12m
Actual	(9.1)	3.5	(29.4)
Relative*	(5.2)	9.2	(29.1)

* % Relative to local index

Analyst

Andy Smith

e-Therapeutics (ETX)

INVESTMENT SUMMARY

e-Therapeutics (ETX) offers investors an exposure to a proprietary, cutting-edge in silico drug discovery platform that has already attracted significant investment and has been fully operational since 2014. This second-generation platform has generated two new chemical entities (NCEs) in immunoncology that are the subject of business development efforts and the cusp of commercial validation. The priority for the company is securing partnership deals to provide external validation of this approach. ETX's strength is its discovery capability, particularly in complex disease networks.

INDUSTRY OUTLOOK

Network-driven approaches could revolutionise drug discovery and shorten the path to market by minimising technical risks and drug development costs. ETX is differentiated from its competitors through its expertise in curating, processing and analysing data in the context of mechanistic modelling of disease.

Y/E Jan	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2017	0.0	(14.2)	(14.1)	(4.1)	N/A	N/A
2018	0.0	(6.7)	(6.7)	(2.0)	N/A	N/A
2019e	0.0	(5.9)	(6.0)	(1.7)	N/A	N/A
2020e	0.0	(4.0)	(4.0)	(1.2)	N/A	N/A

Sector: Pharma & healthcare

Price: NIS1.02
Market cap: NIS237m
Market: TASE

Share price graph (NIS)

Company description

Elbit Medical Technologies is an Israeli biomedical and healthcare technology group. Its portfolio of two companies is focused on medical devices and therapeutics: InSightec, which develops and markets the ExAblate platform for non-invasive thermal tissue ablation, and Gamida Cell, which is developing a universal bone marrow transplant.

Price performance

%	1m	3m	12m
Actual	(2.9)	(4.5)	(0.2)
Relative*	(6.3)	(9.3)	(12.5)

* % Relative to local index

Analyst

Maxim Jacobs

Elbit Medical Technologies (EMTC)

INVESTMENT SUMMARY

Elbit Medical Technologies is an Israel-based healthcare investment company. It is currently invested in two private companies. The company holds a ~22% (~18.5% fully diluted) stake in InSightec, a commercial-stage medical device company. InSightec's ExAblate uses MRI and high-intensity focused ultrasound to perform precise and incisionless thermal tissue ablation. ExAblate has achieved FDA and CE approval for three distinct indications, with revenues of \$32.1m for FY17. The company is also invested in Gamida Cell (~18% owned, ~13% fully diluted), which is developing NiCord, a product derived from umbilical cord blood (UCB) stem cells, for the treatment of high-risk haematological malignancies. Enrolment is underway for a Phase III study with enrolment expected to be complete in H219.

INDUSTRY OUTLOOK

Elbit Medical Technologies is invested in the healthcare sector through its holdings in two companies that are developing medical device and therapeutic technologies.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(0.6)	(3.7)	0.0	N/A	N/A
2017	0.0	(0.7)	(5.2)	0.0	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: 4350.0p
Market cap: £2894m
Market: AIM, NASDAQ

Share price graph (p)

Company description

Hutchison China MediTech (HCM) is an innovative China-based biopharma company targeting the global market for novel, highly selective oral oncology and immunology drugs. Its established China Healthcare business is growing ahead of the market. HCM is the healthcare arm of CK Hutchison (c 40% listed on AIM and NASDAQ).

Price performance

%	1m	3m	12m
Actual	(11.4)	(8.6)	15.3
Relative*	(7.6)	(3.5)	15.9

* % Relative to local index

Analyst

Dr Susie Jana

Hutchison China MediTech (HCM)

INVESTMENT SUMMARY

HCM has built a substantial pipeline of potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, some of which are in development with strategic partners. Lead TKI asset, fruquintinib has received China registration approval from the National Medicinal Products Administration of China (NMPA) for the treatment of CRC (3L). The molecular epidemiology study data on savolitinib in PRCC could support a US NDA submission (possible breakthrough therapy designation). The recent expansion of its US and international operations (US office in New Jersey and the appointment of US CMO and head of international operations) will enable HCM to execute its international R&D and commercialisation strategies for its wholly owned late-stage oncology assets, which we expect will reach value inflection points over the next few years.

INDUSTRY OUTLOOK

HCM's profitable Chinese healthcare business continues to benefit from the fast-growing domestic market, while the clinical, regulatory and technological environments are highly conducive to novel drug development. In the longer term, if the oncology and immunology pipeline comes to fruition, we expect HCM to become a major China and international oncology company.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	216.1	(44.3)	(47.4)	19.6	285.6	N/A
2017	241.2	(50.7)	(53.5)	(43.3)	N/A	N/A
2018e	162.5	(94.8)	(99.5)	(109.5)	N/A	N/A
2019e	180.1	(113.9)	(120.1)	(139.4)	N/A	N/A

Sector: Pharma & healthcare

Price: €0.46
Market cap: €22m
Market: Euronext Growth

Share price graph (€)

Company description

Hybrigenics is a French biotech company. It is developing its lead drug, inecalcitol, against orphan adult leukaemias and is currently conducting an international Phase II study in acute myeloid leukaemia. The company has a research programme on USP inhibitors and an R&D collaboration with Servier focused on USP inhibitors in oncology.

Price performance

%	1m	3m	12m
Actual	(0.9)	(7.0)	(23.2)
Relative*	0.5	(5.0)	(25.1)

* % Relative to local index

Analyst

Juan Pedro Serrate

Hybrigenics (ALHYG)

INVESTMENT SUMMARY

Hybrigenics has adopted a development strategy with vitamin D3 derivative inecalcitol, focusing on adult haematological cancers. In addition to chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML), Hybrigenics is prioritising acute myeloid leukaemia (AML) given inecalcitol's orphan status in the US and Europe and the scarcity of treatment options in this aggressive and difficult to treat leukaemia. Inecalcitol has the potential to enhance rather than replace approved therapies, particularly with its benign safety profile. The company has refocused exclusively on R&D after the MBO of its subsidiary dedicated to proteomic services. Cash position at end December 2017 was €7m.

INDUSTRY OUTLOOK

An international Phase II study in AML has completed recruitment. Interim futility data are expected potentially in December 2018 and full data in mid-2019. Final data from a Phase II in CML was presented: 20% of patients who had completed one year in the study achieved a deep molecular response (DMR) which may allow patients to discontinue treatment (functional cure). Finally, the collaboration with Servier on inhibitors of ubiquitin-specific proteases for oncology is ongoing; up to €12m in potential payments is associated with this programme until registration.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	2.6	(3.5)	(4.0)	(11.2)	N/A	N/A
2017	1.9	(6.8)	(7.3)	(17.7)	N/A	N/A
2018e	3.6	(3.5)	(4.1)	(8.7)	N/A	N/A
2019e	2.2	(3.3)	(4.0)	(7.6)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK7.57
Market cap: SEK386m
Market: OMX

Share price graph (SEK)

Company description

Immunomic is a clinical-stage immunoncology company based in Gothenburg, Sweden. The company is developing an allogeneic dendritic cell immune primer for use in combination with tyrosine kinase inhibitors and checkpoint inhibitors in multiple solid tumour indications.

Price performance

%	1m	3m	12m
Actual	(1.9)	13.0	(42.4)
Relative*	(2.7)	9.1	(45.6)

* % Relative to local index

Analyst

Andy Smith

Immunomic (IMMU)

INVESTMENT SUMMARY

Immunomic is a Sweden-listed, clinical-stage immunoncology (IO) company that develops allogeneic dendritic cell (DC) technologies. Its first clinical product, ilixadencel, is in Phase I and II combination studies in several solid tumour indications. Two studies are expected to report in 2019; the first is the Phase II MERCEA data in renal cell carcinoma (in combination with sunitinib). Interim data from the Phase I/II multi-indication study where ilixadencel is being tested in combination with a checkpoint inhibitor are also expected in H219.

INDUSTRY OUTLOOK

IO is a frenetic pharmaceutical development area with many clinical combination studies being conducted by big pharmaceutical companies. Investors may not need to wait until 2019 for price-moving events depending on the announcements on the start of their combination studies.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	N/A	N/A	N/A	N/A	N/A	N/A
2017	0.0	(80.7)	(80.3)	(309.0)	N/A	N/A
2018e	0.0	(80.7)	(91.2)	(190.6)	N/A	N/A
2019e	0.0	(82.9)	(78.3)	(153.7)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK180.20
Market cap: SEK3121m
Market: NASDAQ OMX First North

Share price graph (SEK)

Company description

Immunovia is a Swedish company, specialised in diagnostics for oncology and autoimmune diseases. Its main product is IMMray PanCan-d, an antibody microarray based on its proprietary IMMray platform. A prospective trial in high-risk patients will start in Q416. The company expects to generate initial out-of-pocket sales in 2018.

Price performance

%	1m	3m	12m
Actual	(29.9)	3.2	72.9
Relative*	(30.4)	(0.4)	63.2

* % Relative to local index

Analyst

Juan Pedro Serrate

Immunovia (IMMUNOV)

INVESTMENT SUMMARY

Immunovia is developing IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. Immunovia is running the PANFAM-1 prospective trial in high-risk patients and expects to generate initial self-pay sales in Q418. Immunovia is conducting a retrospective study with Lund University Diabetes Centre, to compare diabetes patients who developed pancreatic cancer with those who did not. Immunovia is also running the prospective PANDIA-1 study in patients >50 years old with new onset diabetes. Immunovia and the University College London have started collecting samples from patients with early symptoms which is the initial part of the prospective PANSYM-1 study. Additionally, IMMray has potential in immune diseases and lung cancer. The company's shares are listed on Nasdaq Stockholm. Cash and equivalents at end-June 2018 were SEK447.2m.

INDUSTRY OUTLOOK

Immunovia is targeting a potential opportunity of over SEK41bn. It will first target patients with a family history of pancreatic cancer, or other pancreatic diseases with increased risk of cancer (estimated at 200,000 in the EU/US) followed by patients over 50 years of age diagnosed with type 2 diabetes, (estimated at 3.4 million new patients per year) and patients with early gastric symptoms (estimated 1m tests).

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	24.5	(14.4)	(14.7)	(98.0)	N/A	N/A
2017	24.2	(44.3)	(45.2)	(267.0)	N/A	N/A
2018e	29.9	(72.5)	(74.2)	(400.0)	N/A	N/A
2019e	22.6	(85.8)	(88.8)	(456.0)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.04
Market cap: A\$98m
Market: ASX

Share price graph (A\$)

Company description

Immutech has a pipeline of four LAG-3 related product candidates: eftilagimod alpha (IMP321) for cancer chemo-immunotherapy and immunotherapy-immunotherapy combinations, two partnered products IMP731 (GSK) and IMP701 (Novartis), as well as IMP761 for autoimmune diseases.

Price performance

%	1m	3m	12m
Actual	17.1	20.6	95.2
Relative*	19.2	17.8	80.4

* % Relative to local index

Analyst

Dr Dennis Hulme

Immutech (IMM)

INVESTMENT SUMMARY

Immutech has three promising candidates in clinical trials and one preclinical asset, all based on Lymphocyte activation gene-3, LAG-3 (one partnered with GSK and a second partnered with Novartis). Lead in-house LAG-3 product, eftilagimod alpha (IMP321), is being developed in metastatic breast cancer combined with chemo (126 of 226 patients recruited in randomised Phase IIb, initial PFS data expected 2019) and in melanoma in combination with Keytruda (33% response rate in three dose-finding cohorts, 61% response rate from start of Keytruda monotherapy screening; additional six-patient cohort is being treated at the highest dose starting on day 1 of Keytruda treatment). Novartis and GSK are progressing clinical trials of partnered LAG-3 programmes: GSK has announced ulcerative colitis as lead indication; Novartis has commenced two Phase II studies with LAG525 this year and a third is expected to start this month. Immutech will collaborate with Merck (MSD) in a study of IMP321 plus Keytruda in lung and head and neck cancers in H218.

INDUSTRY OUTLOOK

Immunotherapies are among the most promising class of products for cancer and autoimmune diseases. The LAG-3 products are potentially first-in-class, each with distinct mechanisms and applications.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	4.1	(7.8)	(8.4)	(0.4)	N/A	N/A
2018	6.9	(11.4)	(10.9)	(0.5)	N/A	N/A
2019e	10.9	(7.6)	(6.9)	(0.2)	N/A	N/A
2020e	2.8	(15.3)	(14.9)	(0.5)	N/A	N/A

Sector: Pharma & healthcare

Price: C\$0.78
Market cap: C\$133m
Market: TSX

Share price graph (C\$)

Company description

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its platform may be able to produce cannabinoids for less cost and with improved purity compared to currently used methods. The company is developing a pipeline, including INM-750 for epidermolysis bullosa, a serious, debilitating orphan indication.

Price performance

%	1m	3m	12m
Actual	6.9	(13.3)	77.3
Relative*	8.5	(11.9)	67.6

* % Relative to local index

Analyst

Maxim Jacobs

InMed Pharmaceuticals (INM)

INVESTMENT SUMMARY

InMed is a Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Through its biosynthesis platform, the company believes it has distinct advantages over both naturally sourced and chemically synthesized cannabinoids, which could give it access to both the medical and retail markets, although the process is still in development. The company is also developing a proprietary pipeline, including INM-750 for epidermolysis bullosa (EB), a serious orphan indication, and expects to file an IND for INM-750 in H219.

INDUSTRY OUTLOOK

The market for cannabinoids, whether FDA-approved, medical or recreational is growing at a fantastic rate. Legal cannabis sales in the US alone were around \$7.5 billion in 2017 and we expect it to grow to \$28 billion by 2023.

Y/E Jun	Revenue (C\$m)	EBITDA (C\$m)	PBT (C\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	0.0	(3.3)	(3.2)	(3.27)	N/A	N/A
2018	0.0	(5.5)	(5.3)	(3.74)	N/A	N/A
2019e	0.0	(7.6)	(7.5)	(4.20)	N/A	N/A
2020e	0.0	(11.6)	(11.5)	(6.19)	N/A	N/A

Sector: Pharma & healthcare

Price: NIS14.90
Market cap: NIS495m
Market: TASE

Share price graph (NIS)

Company description

Intec Pharma is a drug delivery company that has developed the accordion pill, a novel gastroretentive controlled release formulation. The company is currently using this technology to develop AP-CDLD for Parkinson's in Phase III and AP-ZP for insomnia in Phase II.

Price performance

%	1m	3m	12m
Actual	0.0	(6.2)	(45.2)
Relative*	(3.6)	(10.9)	(52.0)

* % Relative to local index

Analyst

Maxim Jacobs

Intec Pharma (NTEC)

INVESTMENT SUMMARY

Intec Pharma is a drug delivery company that has developed a novel drug delivery device termed the accordion pill (AP), a folded, multilayer membrane packaged into a normal capsule, which expands to a sheet within the stomach to many times its original size. This property causes the pill to be retained in the stomach for up to 12 hours. This is ideal for drugs with local activity in the stomach or upper digestive tract or with poor solubility. AP-CDLD, a controlled release formulation of carbidopa and levodopa for Parkinson's is in Phase III with enrollment expected to complete shortly (currently 95% enrolled) with data in mid-2019.

INDUSTRY OUTLOOK

Parkinson's disease is a neurodegenerative disease in which the dopamine secreting neurons in the brain are lost, leading to severe motor defects and cognitive impairment. Approximately one million people in the US have Parkinson's.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(14.5)	(13.4)	(116.72)	N/A	N/A
2017	0.0	(30.1)	(29.1)	(164.74)	N/A	N/A
2018e	0.0	(31.2)	(29.5)	(93.22)	N/A	N/A
2019e	0.0	(25.0)	(22.8)	(67.94)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.50
Market cap: US\$9m
Market: OTC

Share price graph (US\$)

Company description

International Stem Cell is an early-stage biotechnology company developing therapeutic, biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells (hpSCs). Its lead candidate is a cell therapy treatment for Parkinson's disease.

Price performance

%	1m	3m	12m
Actual	(2.0)	(11.8)	(6.3)
Relative*	(4.7)	(15.7)	(19.4)

* % Relative to local index

Analyst

Maxim Jacobs

International Stem Cell (ISCO)

INVESTMENT SUMMARY

International Stem Cell (ISCO) is an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson's disease (PD), and recently completed dosing of the first patient in their third cohort (a total of 9 so far). The company is also expecting to release interim 6-month data from the second cohort around the end of Q318. With its hpSC technology, ISCO has created 15 stem cell lines, each of which is a different HLA type. From this, it creates different cell types such as liver cells, neural cells and three-dimensional eye structures. Sales of its biomedical business were up 103.1% in Q218 to \$2.7m.

INDUSTRY OUTLOOK

ISCO's technology platform is based on human parthenogenetic stem cells (hpSCs). Parthenogenetic stem cells are created from unfertilized human eggs (oocytes) chemically activated to make the cells pluripotent. As hpSCs express fewer parental histocompatibility antigens, they reduce the risk of immune rejection.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	7.2	(4.5)	(4.9)	(33.82)	N/A	N/A
2017	7.5	(4.6)	(4.9)	(145.96)	N/A	N/A
2018e	11.2	(3.2)	(3.9)	(61.12)	N/A	N/A
2019e	12.2	(6.7)	(8.2)	(122.34)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.44
Market cap: A\$21m
Market: ASX

Share price graph (A\$)

Company description

Kazia Therapeutics has two clinical stage anti-cancer drugs GDC-0084 (targeting glioblastoma) and Cantrixil (targeting ovarian cancer) and a discovery-stage anti-tropomyosins program. GDC-0084 was inlicensed from Genentech, and Kazia is seeking other in-licence opportunities.

Price performance

%	1m	3m	12m
Actual	(10.3)	(31.0)	8.8
Relative*	(8.7)	(32.6)	0.5

* % Relative to local index

Analyst

Dr Dennis Hulme

Kazia Therapeutics (KZA)

INVESTMENT SUMMARY

Kazia Therapeutics is developing two groups of anti-cancer compounds, including GDC-0084, a PI3K inhibitor licensed from Genentech that has been granted orphan designation in the US for glioblastoma. It commenced recruitment in a US-based Phase II program for GDC-0084 in March; an initial Phase IIa dose-optimisation study will precede a randomised Phase IIb trial in 228 first-line glioblastoma patients (final data due 2021). It is also undertaking a Phase I trial of its third generation benzopyran drug Cantrixil. The Phase I trial in ovarian cancer has tentatively identified the MTD and is currently recruiting additional patients to better understand the safety profile, before recruiting a 12-patient expansion cohort. While the primary aim is to assess safety and tolerability, we note that 3/5 patients achieved stable disease after 2 cycles and one achieved a partial response in combination with chemo. Kazia has divested its discovery-stage anti-tropomyosin program to TroBio Therapeutics, and is collaborating with Noxopharm to support the development of NOX66.

INDUSTRY OUTLOOK

Kazia Therapeutics is a biotechnology company listed on the ASX and NASDAQ. Its two main drug technology platforms are third generation benzopyrans and a PI3K inhibitor.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	8.6	(10.2)	(10.9)	(22.81)	N/A	N/A
2018	13.0	(4.9)	(6.3)	(12.48)	N/A	N/A
2019e	3.9	(13.3)	(14.7)	(29.71)	N/A	N/A
2020e	14.0	(7.2)	(8.5)	(16.96)	N/A	N/A

Sector: Pharma & healthcare

Price: €14.30
Market cap: €288m
Market: Euronext Amsterdam

Share price graph (€)

Company description

Kiadis Pharma is a Dutch biotech company developing a modified donor T-cell infusion (ATIR) given after a stem-cell transplant to treat acute leukaemia.

Price performance

%	1m	3m	12m
Actual	57.1	39.6	157.7
Relative*	63.5	46.0	152.5

* % Relative to local index

Analyst

Dr John Savin

Kiadis Pharma (KDS)

INVESTMENT SUMMARY

Kiadis is developing ATIR: an allogeneic donor T-cell preparation that uses its Theralux technology to deplete alloreactive T-cells that can cause Graft vs Host disease (GvHD). The ATIR T-cell preparation is given 28-32 days after a T-cell depleted haploidentical bone marrow transplant, a protocol sometimes used to treat acute leukaemia. ATIR is in a European Phase III study against the clinically favoured 'Baltimore' protocol. The trial is planned to report in H2 2020. A conditional marketing application has been filed with the EMA and an opinion is likely in Q418 as 180 day questions were answered in August. Cash at 30 June 2018 was €41.7m with repayable debt of €15m. A new loan agreement for €20m has been made. Our forecasts are under review.

INDUSTRY OUTLOOK

Zalmoxis, a similar product using a suicide gene switch safety feature, already has a CMA in Europe. There were 2,000 haplo-identical transplants in Europe in 2016. Bellicum's BPX-501 paediatric product should report data by early 2019.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(10.8)	(12.5)	(1105.0)	N/A	N/A
2017	0.0	(14.7)	(17.2)	(1060.0)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €6.25
Market cap: €165m
Market Scale

Share price graph (€)



Company description

MagForce has a European approved nanotechnology-based therapy to treat brain cancer. Nanoparticles are injected into the tumour and activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

Price performance

%	1m	3m	12m
Actual	19.5	14.9	(17.8)
Relative*	22.5	22.8	(14.4)

* % Relative to local index

Analyst

Dr Susie Jana

MagForce (MF6)

INVESTMENT SUMMARY

MagForce is moving forward with its strategy to drive uptake and acceptance (in the US and Europe) of its NanoTherm nanoparticle-based therapy for cancer. In Germany, Magforce has six centres commercially capable (three utilised, c50 patients to date) of treating glioblastoma (GBM) patients. To accelerate uptake of NanoTherm treatment in Europe, MagForce is expanding from Germany into other countries, firstly Poland (Public Clinical Hospital No. 4 in Lublin) and then Italy is anticipated (funded primarily by an up to €35m loan from the European Investment Bank). In the US, its subsidiary Magforce USA has received FDA IDE approval and a pivotal US clinical trial in prostate cancer has enrolled the first patient. Proceeds from the August 2018 Magforce USA capital increase (\$9m gross) will be used in part to finance the US prostate cancer trial.

INDUSTRY OUTLOOK

MagForce's NanoTherm therapy has been designed to directly affect tumours from within, while sparing surrounding healthy tissue. Magnetic nanoparticles are directly injected into a tumour and are then heated in the presence of an external magnetic field generated by specialist equipment (NanoActivator). This can destroy or sensitise the tumour for additional treatment.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.5	(6.6)	(7.2)	(27.8)	N/A	N/A
2017	0.7	(6.7)	(7.5)	(28.3)	N/A	N/A
2018e	2.9	(7.6)	(8.8)	(33.4)	N/A	N/A
2019e	7.1	(6.6)	(7.9)	(30.2)	N/A	N/A

Sector: Pharma & healthcare

Price: €12.77
Market cap: €314m
Market FRA

Share price graph (€)



Company description

Medigene is a German biotech company with a core business in cancer immunotherapy. A T cell receptor (TCR) candidate has recently entered the clinic and a dendritic cell (DC) vaccine Phase I/II clinical study is ongoing in Phase II.

Price performance

%	1m	3m	12m
Actual	(6.5)	(2.4)	7.0
Relative*	(4.2)	4.3	11.5

* % Relative to local index

Analyst

Dr Daniel Wilkinson

Medigene (MDG1)

INVESTMENT SUMMARY

Medigene is focused on the rapid development of its cancer immunotherapy technology platforms: dendritic cell (DC) cancer vaccines, adoptive T-cell therapy (TCR) and T-cell specific antibodies (TAB). A Phase II study is ongoing with DC vaccines for acute myeloid leukaemia. For TCRs, Medigene has initiated its first company-led trial with MDG1011 in patients with PRAME expressing AML, MDS or MM. Its partnership with bluebird bio to utilise its TCR technology platform was recently expanded (US\$8m one time payment, US\$1m achieved milestone payment, US\$250 milestones per target, tiered royalties) to now include six therapeutic candidates. Medigene is well-funded to execute its clinical programme, as of 30th June cash was €80.8m.

INDUSTRY OUTLOOK

Cancer immunotherapy is attracting huge biotech investor interest. Medigene's DC vaccine technology is a new generation, with multiple potential efficacy and manufacturing benefits over the forerunners, eg Provenge. The TCR programme has similarities to CAR-T products, but with potentially significant efficacy and safety advantages.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	9.7	(12.4)	(13.4)	(66.20)	N/A	N/A
2017	11.4	(12.1)	(12.4)	(60.42)	N/A	N/A
2018e	10.4	(18.2)	(17.8)	(76.38)	N/A	N/A
2019e	11.0	(18.0)	(17.2)	(70.41)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$1.64
Market cap: A\$789m
Market: ASX

Share price graph (A\$)

Company description

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas.

Price performance

%	1m	3m	12m
Actual	(3.0)	8.3	18.9
Relative*	(1.4)	6.4	10.6

* % Relative to local index

Analyst

Dr Dennis Hulme

Mesoblast (MSB)

INVESTMENT SUMMARY

The potentially pivotal 55 pediatric patient acute graft vs host disease (GvHD) study met its primary endpoint, with a 69% overall response rate vs 45% for historical controls (p=0.0003). The 180 day safety and duration of response data is expected soon. This is expected to lead to a fast track application to the FDA. The NIH funded Phase IIb in end-stage CHF patients with an LVAD should have full data by Q4 CY18. In March, Mesoblast entered a US\$75m non-dilutive credit facility and has drawn-down \$35m. A June deal gained \$30m plus US\$10m equity based on expected GvHD sales. A collaborative alliance with Tasly on developing MPC for CHF in China has given a US\$20m upfront and US\$20m for an equity subscription. Cash on 30 June was US\$116.8m; cash outflow was US\$75m. We are updating our forecasts.

INDUSTRY OUTLOOK

Mesoblast is the leading mesenchymal stem cell company. It has a manufacturing alliance with Lonza. JCR Pharmaceuticals markets Mesoblast's GvHD therapy in Japan; FY18 royalties were US\$3.6m plus a US\$1.5m milestone.

Y/E Jun	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2017	1.9	(82.2)	(83.3)	(17.69)	N/A	N/A
2018	17.0	(66.2)	(68.6)	(8.35)	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A
2020e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €4.85
Market cap: €37m
Market: FRA

Share price graph (€)

Company description

Mologen is a German biotech company developing cancer immunotherapies. The lead product is lefitolimod (MGN1703) for metastatic colorectal cancer maintenance, SCLC and HIV. Development of MGN1601, a therapeutic renal cell vaccine, would be reinitiated on successful out-licensing of lefitolimod.

Price performance

%	1m	3m	12m
Actual	(4.1)	(46.4)	(76.5)
Relative*	(1.4)	(46.7)	(76.7)

* % Relative to local index

Analyst

Dr Susie Jana

Mologen (MGN)

INVESTMENT SUMMARY

Mologen is developing novel immunotherapies for use in the post-chemo maintenance setting in cancer and for the treatment of infectious diseases. Mologen's efforts are focused on its lead product candidate lefitolimod. IMPALA a 540-pt pivotal study in metastatic colorectal cancer (mCRC) maintenance has completed full enrollment. A 60-patient Phase I combination study of lefitolimod with Yervoy in solid tumours is now being conducted by MD Anderson, enrollment has started. Gross cash of €6.2m as of 30 June 2018. Mologen has signed a variety of financial agreements and the deal terms on a global partnership with Oncologie (€23m near term considerations, over €1bn in milestones, plus royalties on net sales). Funding from these in addition to the €18m proposed capital raise implies a current gross cash position of c€28m.

INDUSTRY OUTLOOK

Results for IMPALA are expected in 2018/19. Final overall survival (OS) data from IMPACT (Phase II in mCRC) and IMPULSE may offer fresh financing/partnering opportunities for lefitolimod before then.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.1	(20.6)	(20.8)	(0.84)	N/A	N/A
2017	0.0	(18.7)	(19.3)	(0.56)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pcare & household prd

Price: 31.0p
Market cap: £24m
Market: AIM

Share price graph (p)

Company description

NetScientific is a transatlantic biomedical and healthcare technology group. Its portfolio of five core investments and one material investment is focused on three main sectors: digital health (Wanda), diagnostics (Vortex, ProAxis, Glycotest) and therapeutics (PDS Biotech).

Price performance

%	1m	3m	12m
Actual	(12.9)	(31.9)	(25.3)
Relative*	(9.2)	(28.1)	(24.9)

* % Relative to local index

Analyst

Maxim Jacobs

NetScientific (NSCI)

INVESTMENT SUMMARY

NetScientific has a focused portfolio of potentially disruptive biomedical and healthcare technology investments. Recent years saw significant strategic changes, including senior management restructuring, with a new highly experienced CEO on board, rationalisation of the portfolio and new funding. The current focus is on digital health, diagnostics and therapeutics with the portfolio consisting of four core investments in which it has controlling stakes (Vortex, Wanda, ProAxis and Glycotest) and one material investment (PDS). The aim is to bring these to commercialisation over the next two years, with the ultimate goal of an exit, realising value for investors. Vortex recently made its first commercial sale of the VTX-1 liquid biopsy system and ProAxis reported strong sales growth.


INDUSTRY OUTLOOK

NetScientific remains focused on sourcing, funding and building early- to mid-stage US and UK companies that are developing potentially breakthrough technologies in growing markets with unmet needs.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	0.5	(12.6)	(12.3)	(20.6)	N/A	N/A
2017	0.4	(10.8)	(9.5)	(13.6)	N/A	N/A
2018e	1.9	(11.5)	(12.4)	(13.5)	N/A	N/A
2019e	4.1	(8.3)	(9.7)	(10.8)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK3.96
Market cap: SEK363m
Market: NASDAQ OTCQX

Share price graph (SEK)

Company description

NeuroVive Pharmaceutical is a Swedish biopharmaceutical company with deep expertise in mitochondrial medicine. It has a diversified portfolio in terms of indications and employs a dual strategy: it develops a core portfolio of assets for orphan diseases and seeks to out-license proprietary products for non-orphan indications.

Price performance

%	1m	3m	12m
Actual	(21.1)	20.2	14.9
Relative*	(21.7)	16.0	8.6

* % Relative to local index

Analyst

Dr Jonas Peculis

NeuroVive Pharmaceutical (NVP)

INVESTMENT SUMMARY

NeuroVive Pharmaceutical is a mitochondrial medicine specialist. NeuroVive's core portfolio targets orphan indications: traumatic brain injury with NeuroSTAT, various genetic mitochondrial diseases with KL1333 and NVP015, and mitochondrial myopathy with NVP025. On 6 September, NeuroVive received positive feedback from the FDA on its NeuroSTAT TBI development plan including the design of the Phase IIb proof-of-concept study. This study is expected to start in H218/H119. The second most advanced product KL1333, in-licensed from Yungjin Pharm in May 2017, demonstrated positive results in the Phase I trial in South Korea and NeuroVive is planning to start a Phase Ib study in H218. Recent highlight is an out-licensing of a subset of compounds from NVP015 program for localized treatment of LHON to BridgeBio Pharma for a deal value of around \$60m. Other products for out-licensing include NV556 and NVP022 for NASH and NVP024 for hepatocellular carcinoma.


INDUSTRY OUTLOOK

NeuroVive has a diversified portfolio with all assets aimed at improving mitochondrial metabolism and function. This puts NeuroVive among the very few experts in mitochondrial medicine in the industry, in our view.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	0.0	(69.9)	(70.7)	(172.27)	N/A	N/A
2017	0.6	(67.9)	(70.1)	(149.31)	N/A	N/A
2018e	0.6	(83.5)	(83.6)	(132.64)	N/A	N/A
2019e	0.6	(132.0)	(132.2)	(170.66)	N/A	N/A

Sector: Pharma & healthcare

Price: CHF9.75
Market cap: CHF174m
Market Swiss Stock Exchange

Share price graph (CHF)

Company description

Newron is a CNS-focused biotech. Xadago (partnered with Zambon, US WorldMeds, Meiji Seika, Sequirus) for PD has been launched in Europe and the US. Other pipeline assets include Sarizotan (Phase III for RS) and Evenamide (Phase II for schizophrenia).

Price performance

%	1m	3m	12m
Actual	(13.1)	(17.4)	(46.9)
Relative*	(12.7)	(20.4)	(46.3)

* % Relative to local index

Analyst

Dr Susie Jana

Newron Pharmaceuticals (NWRN)

INVESTMENT SUMMARY

Newron's lead product, Xadago (safinamide) for Parkinson's disease (PD) has been launched in 14 European countries and is generating sales through commercial partner Zambon (ex-Japan/Asia). Additionally, Xadago has been launched in the US by sublicensee US WorldMeds. Following positive phase II/III data (Japan), partner Meiji plan to submit the salfinamide MAA in Japan during 2018. Other pipeline assets include sarizotan for Rett syndrome, the pivotal trial STARS (placebo-controlled Phase II/III trial) to investigate breathing disorders associated with RS has initiated (enrollment expected to complete in H218). Full data from the Phase II study of evenamide as an add-on to atypical antipsychotics, published in March 2017, demonstrated efficacy in terms of improvement on the symptoms of schizophrenia assessed by the Positive and Negative Syndrome Scale (PANSS). Newron raised CHF27m in 2017 in a private placement that it expects will help fund operations through 2019.


INDUSTRY OUTLOOK

Parkinson's disease is a growing market. Xadago could have a unique position, with once-a-day dosing and a clean safety profile.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	6.7	(15.3)	(15.2)	(103.69)	N/A	N/A
2017	13.4	(4.3)	(5.3)	(32.32)	N/A	N/A
2018e	5.6	(24.7)	(24.5)	(137.90)	N/A	N/A
2019e	10.7	(28.3)	(28.2)	(158.27)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK16.14
Market cap: SEK799m
Market NASDAQ OMX First North

Share price graph (SEK)

Company description

Nuevolution is a Copenhagen-based biopharmaceutical company. Its patent protected Chemetics drug discovery platform enables the selection of drugs to an array of tough-to-drug disease targets. To date it has entered into 17 agreements with major pharmaceutical companies.

Price performance

%	1m	3m	12m
Actual	(0.6)	(2.2)	0.9
Relative*	(1.4)	(5.6)	(4.7)

* % Relative to local index

Analyst

Dr Daniel Wilkinson

Nuevolution (NUE)

INVESTMENT SUMMARY

Nuevolution's proprietary Chemetics DNA-encoded screening platform technology enables fast and accurate small molecule drug discovery. The technology has received powerful external validation, including three recent collaborations (Amgen, Almirall and Janssen) that could generate significant value in the coming years. In addition, we expect Nuevolution to progress at least one internally generated asset into clinical development in the near future. Net cash of SEK 131.0m as of 30th June 2018.

INDUSTRY OUTLOOK

Significant promise is seen in DNA-encoded libraries due to the potential to rapidly develop small molecule drugs to 'tough-to-drug' targets. We continue to see major investment in the space from an array of companies, notably GSK, Roche and Novartis.

Y/E Jun	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	21.3	N/A	(151.9)	(4.0)	N/A	N/A
2017	120.3	N/A	(9.4)	(0.6)	N/A	N/A
2018e	104.9	N/A	(32.1)	(0.5)	N/A	N/A
2019e	229.2	N/A	87.6	1.3	1241.5	8.6

Sector: Pharma & healthcare

Price: SEK11.70
Market cap: SEK286m
Market NASDAQ OMX First North

Share price graph (SEK)



Company description

Oncology Venture is a biopharmaceutical company with a patent-protected mRNA-based drug response predictor platform that identifies patients highly likely to respond to treatment. The company is entering Phase II with six in-licensed drugs.

Price performance

%	1m	3m	12m
Actual	25.3	24.2	(4.5)
Relative*	22.9	20.1	(10.1)

* % Relative to local index

Analyst

Dr Nathaniel Calloway

Oncology Venture (OV.ST)

INVESTMENT SUMMARY

Oncology Venture holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to identify potential responders to different cancer therapies. The company's goal is to then identify and in-license drugs that are active within populations that the DRP can identify. To date, the company has in-licensed six drugs and is in the early stages of validating the platform in the clinic.

INDUSTRY OUTLOOK


Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost, which the company may then out-license after clinical validation.

Y/E Dec	Revenue (DKKm)	EBITDA (DKKm)	PBT (DKKm)	EPS (ore)	P/E (x)	P/CF (x)
2016	N/A	N/A	N/A	N/A	N/A	N/A
2017	5.1	(23.8)	(31.0)	(127.00)	N/A	N/A
2018e	5.1	(36.5)	(36.5)	(67.85)	N/A	N/A
2019e	2.4	(198.6)	(200.6)	(354.76)	N/A	N/A

Sector: Pharma & healthcare

Price: €1.07
Market cap: €54m
Market Euronext Paris

Share price graph (€)



Company description

Onxeo is developing innovative oncology drugs based on DNA-targeting and epigenetics. The lead compound, AsiDNA, is a first-in-class DNA break repair inhibitor based on a unique decoy mechanism and currently evaluated in a phase I trial (DRIIV-1) for systemic administration in solid tumors.

Price performance

%	1m	3m	12m
Actual	(9.5)	(20.2)	(51.5)
Relative*	(8.3)	(18.5)	(52.7)

* % Relative to local index

Analyst

Dr Jonas Peculis

Onxeo (ONXEO)

INVESTMENT SUMMARY

Onxeo's lead asset AsiDNA, a first-in-class DNA break repair inhibitor, is currently being tested in Phase I DRIIV-1 trial at the Institut Curie in Paris in patients with advanced solid tumours. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection, but is now being tested via systemic administration. Onxeo is conducting a broad preclinical programme that explores AsiDNA in various settings and combinations with other drugs. AsiDNA is part of the proprietary, novel platON platform, a major R&D expansion announced in October 2017, and is based on decoy oligonucleotides. The platON platform belongs to the so-called DNA damage response (DDR) technology, a domain to which recently marketed PARP inhibitors also belong. Recently, Onxeo received \$7.5m after the sale of rights to royalties from Beleodaq and gained access to €5.4m equity financing line extending cash reach to Q320 past the AsiDNA Phase I results.

INDUSTRY OUTLOOK

The approval of the first PARP inhibitor (olaparib) has kick started the interest of both the scientific community and large pharma in the DNA Damage Response (DDR) field. Few biotechs are already positioned in this emerging field which may be the successor to immuno-oncology.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	4.4	(21.3)	(20.4)	(44.64)	N/A	N/A
2017	9.5	(17.4)	(19.7)	(23.58)	N/A	N/A
2018e	2.6	(12.1)	(12.2)	(24.20)	N/A	N/A
2019e	3.9	(11.1)	(11.2)	(22.26)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK72.90
Market cap: SEK2519m
Market NASDAQ OMX Mid Cap

Share price graph (SEK)



Company description

Orexo is a Swedish speciality pharma company, with expertise in drug delivery/reformulation technologies (in particular sublingual formulations) and a US commercial infrastructure for opioid dependence therapy Zubsolv (also filed in Europe). Orexo also has two clinical assets and three preclinical programmes.

Price performance

%	1m	3m	12m
Actual	54.5	115.7	135.2
Relative*	53.3	108.2	122.1

* % Relative to local index

Analyst

Andy Smith

Orexo (ORX)

INVESTMENT SUMMARY

Orexo generated positive EBITDA and operating cash flow generation in FY16 and FY17, and have guided for this to continue in FY18. US commercial and public formulary coverage is dynamic but exclusive contracts with Humana, among other insurers, are having a positive impact on US Zubsolv volumes and sales. IP infringement litigation remains as an overhang but delays in the appeal judgement may be a relief. An Actavis generic launch before September 2019 is precluded; multiple cases are ongoing or, in the case of the '330 patent, under final appeal expected Q318. The EMA has approved Zubsolv for Europe, and partner Mundipharma launched in Q218 with the SEK30.6m milestone now in our model. EU Zubsolv royalties are expected to start in H218.

INDUSTRY OUTLOOK


Opioid dependence diagnosis/treatment rates are low due to social stigma, limited access to therapy in parts of the US and affordability. Competition includes Suboxone film (Indivior), Bunavail (BDSI) and six generic bup/nal tablets.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	705.9	51.7	35.6	84.00	86.8	N/A
2017	643.7	57.4	29.7	67.00	108.8	N/A
2018e	814.0	115.6	109.0	288.76	25.2	N/A
2019e	949.4	198.2	159.8	447.93	16.3	N/A

Sector: Pharma & healthcare

Price: €3.93
Market cap: €134m
Market Madrid Stock Exchange

Share price graph (€)



Company description

Oryzon Genomics is a Spanish biotech focused on epigenetics. Ladademstat (ORY-1001, Phase IIa) is being explored for acute leukaemias and SCLC; Vafidemstat (ORY-2001) is in Phase IIa for AD and MS, and ORY-3001 is being developed for certain orphan indications.

Price performance

%	1m	3m	12m
Actual	6.8	35.1	88.0
Relative*	9.1	43.3	109.0

* % Relative to local index

Analyst

Dr Jonas Peculis

Oryzon Genomics (ORY)

INVESTMENT SUMMARY

Oryzon's expertise lies in developing small molecule inhibitors for epigenetic targets. Oryzon's lead CNS product vafidemstat (ORY-2001), a dual LSD1/MAOB inhibitor, targets Alzheimer's disease (Phase IIa initiated), multiple sclerosis (Phase IIa initiated) and other neurodegenerative indications. Results from both trials are expected in 2019. Oryzon has also recently received CTA approval to carry out a Phase IIa trial studying vafidemstat (ORY-2001) in aggressiveness. The lead oncology product iadademstat (ORY-1001) is a specific LSD1 inhibitor with positive data from the Phase I/IIa in acute leukaemia announced in December 2016. On 10 September Oryzon announced the initiation of a Phase IIa trial in AML and plans to initiate a second Phase IIa trial in SCLC in the coming months. The cash position was €31.0m at end Q218.

INDUSTRY OUTLOOK

Epigenetics is a relatively young field in terms of drug development. HDACs were among the first epigenetic therapeutics brought to market, and although effective, they have side effects. Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and are expected to show a favourable safety/efficacy profile.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	5.0	(3.7)	(4.7)	(17.02)	N/A	N/A
2017	4.3	(3.5)	(4.6)	(14.29)	N/A	N/A
2018e	7.0	(4.7)	(5.6)	(16.34)	N/A	N/A
2019e	6.3	(6.4)	(7.3)	(21.26)	N/A	N/A

Sector: Pharma & healthcare

Price: 924.0p
Market cap: £610m
Market: LSE

Share price graph (p)

Company description

Oxford BioMedica's (OXB) LentiVector technology underpins the company's strategy. OXB generates significant revenue from partners that utilise its technology, notably Novartis, Bioverativ, Orchard Therapeutics and Immune Design. OXB is in partnering discussions about internally developed assets.

Price performance

%	1m	3m	12m
Actual	7.1	(8.6)	130.1
Relative*	10.8	(3.2)	128.1

* % Relative to local index

Analyst

Dr Daniel Wilkinson

Oxford BioMedica (OXB)

INVESTMENT SUMMARY

In 2018, Oxford BioMedica (OXB) aims to maintain its position as a global leader in lentiviral development and manufacturing. On the back of a £20.5m gross raise, OXB is expanding its manufacturing capabilities to match increasing demand. The additional capacity will enable OXB to continue the rapid growth of its platform (partnership) revenues. In the near term, revenue will continue to be driven by the Novartis partnership as Kymriah's commercial roll out continues (royalties and manufacturing fees). OXB continues to look for spin-out/out-licensing of its priority internal pipeline assets. Notably, OXB-102 in Parkinson's disease has now been out-licensed to Axovant (\$30m upfront, \$757.7m milestones, 7% to 10% royalties). The company recently announced a partnership with Bioverativ (in field of haemophilia) potentially worth in excess of \$100m. As of 30 June, OXB has gross £44.0m in cash.

INDUSTRY OUTLOOK

Cell- and gene-therapy is the focus of much industry attention as it can dramatically alter the outcomes of many diseases. The proprietary lentivector platform has demonstrated promise in many indications.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	27.8	(7.6)	(20.0)	(29.35)	N/A	N/A
2017	37.6	(1.3)	(11.5)	(14.14)	N/A	N/A
2018e	72.5	14.0	4.5	9.88	93.5	64.4
2019e	82.9	19.0	7.7	14.81	62.4	37.0

Sector: Pharma & healthcare

Price: NZ\$0.31
Market cap: NZ\$150m
Market: NZSX

Share price graph (NZ\$)

Company description

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

Price performance

%	1m	3m	12m
Actual	3.3	46.5	(34.1)
Relative*	0.5	43.2	(42.1)

* % Relative to local index

Analyst

Maxim Jacobs

Pacific Edge (PEB)

INVESTMENT SUMMARY

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests using its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia. The company recently announced that the number of tests processed increased by 29% in FY18 and is guiding for 60% growth in FY19. The company is negotiating agreements with the Centers for Medicare and Medicaid as well as private payers to provide for improved reimbursement, which would be a major driver in the future.

INDUSTRY OUTLOOK

Molecular diagnostics is a growing, but increasingly competitive field. Lead time from the initiation of user programmes to payment can be long.

Y/E Mar	Revenue (NZ\$m)	EBITDA (NZ\$m)	PBT (NZ\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	4.4	(22.3)	(22.4)	(5.9)	N/A	N/A
2018	4.8	(19.4)	(19.5)	(4.4)	N/A	N/A
2019e	7.8	(17.9)	(17.7)	(3.7)	N/A	N/A
2020e	12.7	(14.1)	(14.2)	(2.8)	N/A	N/A

Sector: Pharma & healthcare

Price: €2.40
Market cap: €153m
Market: FRA

Share price graph (€)



Company description

PAION is a specialty pharma company developing anaesthesia products. Its lead product, remimazolam, is partnered with Mundipharma in Japan, Yichang in China, Hana Pharma in S Korea, Cosmo in the US, Pendopharm in Canada and R-Pharm in CIS, Turkey and MENA.

Price performance

%	1m	3m	12m
Actual	(2.0)	14.3	(16.3)
Relative*	0.4	22.2	(12.8)

* % Relative to local index

Analyst

Dr Dennis Hulme

Paion (PA8)

INVESTMENT SUMMARY

Paion reported positive results from Phase III trials of remimazolam for procedural sedation in bronchoscopy and colonoscopy and has completed its US clinical development program. In the bronchoscopy trial 82.5% of patients on remimazolam achieved the primary outcome vs 3.4% on placebo and 34.8% on midazolam. While replacing midazolam as the primary target, planned US reimbursement changes favouring less supervision of sedation by anaesthetists could further incentivise uptake of remimazolam. In December 2017 Paion outlicensed Japanese rights to Mundipharma, which will bear the cost of market authorisation (filing for general anaesthesia expected in H218). Paion has initiated a Phase III study in GA in Europe, with top-line data expected in 2019. Cash of €23.3m at 30 June and anticipated milestone revenue is sufficient to file for procedural sedation in the US (filing by partner Cosmo expected Q418/Q119) and report top-line data from the European Phase III.

INDUSTRY OUTLOOK

Remimazolam has important advantages over competing products, including fast onset and offset of action with lower risk of cardiopulmonary events than the standard of care midazolam and propofol, and a reversal agent exists if there is over sedation.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	4.3	(25.1)	(25.1)	(37.8)	N/A	N/A
2017	5.8	(15.9)	(15.9)	(20.5)	N/A	N/A
2018e	3.1	(16.7)	(16.6)	(21.8)	N/A	N/A
2019e	10.5	(6.4)	(6.4)	(6.4)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$2.33
Market cap: US\$339m
Market: NASDAQ

Share price graph (US\$)



Company description

PDL has reinvented itself through a three-pronged strategy: investing in royalty streams of marketed and development-stage therapeutics and providing high-yield debt financing to device & diagnostic companies with near-term product launches.

Price performance

%	1m	3m	12m
Actual	(1.7)	(13.7)	(27.4)
Relative*	(4.5)	(17.5)	(37.6)

* % Relative to local index

Analyst

Maxim Jacobs

PDL BioPharma (PDLI)

INVESTMENT SUMMARY

PDL BioPharma is a healthcare-focused finance company with a three-pronged strategy: investing in royalty streams, providing high-yield financing to life science companies with near-term product launches as well as purchasing approved drugs to be sold by Noden Pharma (which is currently a wholly owned subsidiary) on a high margin basis. This strategy allows investors to gain exposure in healthcare through a relatively low-risk, diversified vehicle. PDL reported Q218 revenues of \$46.6m, with Noden product revenue of \$25.9m (up 45.1% compared to Q118). Almost all of that growth came from increased sales in Asia thanks to the launch in Japan by distribution partner Orphan Pacific. Lee's Pharmaceutical Holdings, Noden's partner in China, Hong Kong, Macau and Taiwan, is expected to launch Tektura/Rasilez in China in H119.

INDUSTRY OUTLOOK

PDL BioPharma is one of the only companies that will give broad exposure to diverse royalty streams as well as corporate debt and high margin approved products.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	244.3	193.1	175.5	77.72	3.0	3.8
2017	320.1	218.8	200.3	81.33	2.9	8.9
2018e	176.1	53.7	47.8	37.10	6.3	N/A
2019e	145.5	38.5	41.1	23.40	10.0	N/A

Sector: Pharma & healthcare

Price: €1.56
Market cap: €346m
Market Madrid Stock Exchange

Share price graph (€)



Company description

PharmaMar is a Spanish biopharmaceutical group with a core focus on the development of marine-based drugs for cancer. Yondelis is approved in the EU and US, and partnered with Janssen (J&J) in the US and Taiho in Japan.

Price performance

%	1m	3m	12m
Actual	(1.2)	(4.5)	(57.9)
Relative*	0.9	1.4	(53.2)

* % Relative to local index

Analyst

Maxim Jacobs

PharmaMar (PHM)

INVESTMENT SUMMARY

PharmaMar has built a pipeline of first-in-class cancer drugs for development with strategic partners. The company presented promising Zepsyre data in small-cell lung cancer (SCLC) patients at ASCO. In a total of 61 patients, the objective response rate was 39.3% with a median duration of response of 6.2 months and median overall survival of 12 months. The 600-patient Phase III ATLANTIS study in relapsed SCLC patients has recently completed recruitment. Data from the ATLANTIS trial is expected around the end of 2019. The company recently announced its intention of listing in the US.

INDUSTRY OUTLOOK

PharmaMar's oncology portfolio has been validated through multiple global partnerships, eg J&J in the US and Taiho in Japan (for Yondelis).

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	164.0	(11.5)	(24.7)	(10.8)	N/A	N/A
2017	162.6	(8.2)	(22.7)	(12.0)	N/A	638.4
2018e	168.8	17.7	5.8	2.6	60.0	N/A
2019e	177.3	19.5	7.2	2.7	57.8	29.5

Sector: Pharma & healthcare

Price: NOK60.00
Market cap: NOK1296m
Market AIM Italia, Oslo

Share price graph (NOK)



Company description

Photocure specialises in photodynamic therapy. Its bladder cancer imaging product is sold as Hexvix in Europe and Cysview in the US. Photocure handles the marketing in Nordic countries and the US, while Ipsen is its marketing partner in the EU.

Price performance

%	1m	3m	12m
Actual	36.5	103.4	150.0
Relative*	35.6	100.4	115.2

* % Relative to local index

Analyst

Maxim Jacobs

Photocure (PHO)

INVESTMENT SUMMARY

Photocure is a commercial-stage Norwegian specialty pharmaceutical company that currently markets Hexvix/Cysview for diagnosing and managing bladder cancer. Recently, the US Centers for Medicare & Medicaid Services (CMS) issued a final rule that would improve reimbursement for a large number of procedures. Also, following positive Phase III results in the surveillance setting, the company received FDA approval for that indication and launched the product in May. Sales may have significant upside if the product successfully expands into the US bladder cancer surveillance market, which has 1.2m-1.4m procedures per year, compared to its current market of 325,000 transurethral resection of the bladder (TURB) procedures.

INDUSTRY OUTLOOK

Photocure is a photodynamic therapy company focused on bladder cancer. As its products typically are a combination of a drug and a device, hurdles for generics are typically higher than with other therapeutics.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	143.6	(8.0)	12.8	164.0	36.6	67.2
2017	150.9	(33.1)	(41.6)	(161.0)	N/A	N/A
2018e	201.5	(1.8)	(14.7)	(40.0)	N/A	N/A
2019e	288.8	73.8	61.0	204.0	29.4	32.4

Sector: Pharma & healthcare

Price: €1.86
Market cap: €39m
Market: Euronext Paris

Share price graph (€)



Company description

Pixium Vision develops bionic retinal implants for patients with severe vision loss. A wireless sub-retinal implant (Prima), designed for Dry-ARMD patients, is in a human feasibility study in Europe and is expected to start a US feasibility study in Q218.

Price performance

%	1m	3m	12m
Actual	11.3	(9.6)	(63.3)
Relative*	12.8	(7.7)	(64.2)

* % Relative to local index

Analyst

Pooya Hemami

Pixium Vision (PIX)

INVESTMENT SUMMARY

Pixium Vision is developing the Prima wireless photovoltaic sub-retinal implant, which transforms images into electrical signals to elicit a form of central visual perception in patients with severe retinal disease. It announced in July 2018 the fifth and final human Prima implantation, as per the protocol of its European feasibility study, designed to assess Prima in patients with advanced atrophic Dry Age-related macular degeneration (ARMD). All five implantations were followed by successful activations (resulting in reported light perception). Pixium plans to start implantations as part of a five-patient US Prima feasibility study in Q318.

INDUSTRY OUTLOOK

In May 2018, Pixium raised €10.6m through the issuance of 5.68m new shares. Pixium held €16.7m in gross cash at 30 June 2018, which we estimate will fund operations through Q419. Prima has been designed and being evaluated in clinical studies as a potential treatment option for Dry-ARMD, a common disease in aging population and a significant unmet medical need.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	2.5	(11.4)	(12.4)	(97.60)	N/A	N/A
2017	2.5	(11.4)	(13.2)	(99.55)	N/A	N/A
2018e	2.2	(6.4)	(7.1)	(40.45)	N/A	N/A
2019e	2.5	(14.4)	(17.1)	(83.34)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.35
Market cap: US\$153m
Market: NASDAQ, TASE

Share price graph (US\$)



Company description

Pluristem is a biotech company, headquartered in Israel, focused on the development of cell-based therapeutics derived from placenta. The company is advancing PLX-PAD for critical limb ischemia (CLI) with a Phase III study on hip fracture. PLX-R18 is being advanced for acute radiation syndrome and hematopoietic cell transplant.

Price performance

%	1m	3m	12m
Actual	8.9	1.5	0.0
Relative*	5.8	(3.0)	(14.0)

* % Relative to local index

Analyst

Maxim Jacobs

Pluristem Therapeutics (PSTI)

INVESTMENT SUMMARY

Pluristem Therapeutics is developing allogenic cell therapies derived from donated placental tissue. The company is advancing PLX-PAD in its Phase III study of critical limb ischemia and recently reported data from its 172-patient Phase II study of intermittent claudication patients. Patients that received two injections of 300m cells showed a statistically significant improvement in maximal walking distance when compared to baseline ($p=0.0008$). Also, the company reported that the revascularization risk was reduced in this arm by 49% at week 65.

INDUSTRY OUTLOOK

Pluristem has been investigating the potential therapeutic benefit of cells derived from the placenta which offers a rich supply of cells of multiple lineages from tissue that would otherwise be medical waste. They secrete a wide array of cytokines and growth factors and can exert a potent influence on the function of other cells in the body.

Y/E Jun	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	2.8	(25.5)	(20.2)	(25.36)	N/A	N/A
2017	0.0	(30.2)	(24.2)	(27.63)	N/A	N/A
2018e	0.1	(34.9)	(19.7)	(18.58)	N/A	N/A
2019e	0.0	(48.2)	(43.9)	(38.38)	N/A	N/A

Sector: Pharma & healthcare

Price: €3.45
Market cap: €28m
Market Euronext Amsterdam

Share price graph (€)



Company description

Probiobdrug is a German biopharmaceutical company developing drugs for AD. Lead product PQ912 has just completed a Phase IIa study with encouraging results. PQ912 is a small molecule inhibitor of glutamyl cyclase (QC), which is essential for the formation of pGlu-Abeta. Two further products are in preclinical stages.

Price performance

%	1m	3m	12m
Actual	8.2	(25.3)	(75.6)
Relative*	12.5	(21.9)	(76.1)

* % Relative to local index

Analyst

Dr Jonas Peciulis

Probiobdrug (PBD)

INVESTMENT SUMMARY

Probiobdrug is developing a clinical pipeline focusing on the novel target of pGlu-Abeta, a toxic variant of amyloid-beta (Abeta) that has been implicated in the initiation and sustainment of the pathological cascade that leads to Alzheimer's disease (AD). Lead candidate PQ912 is an inhibitor of the enzyme glutamyl cyclase, which is essential for the formation of pGlu-Abeta. Initial results from the Phase IIa study, SAPHIR, were reported on 12 June 2017. Probiobdrug has presented detailed Phase IIb development with the next trial planned to start by end-2018, depending on financing. Preclinical data also showed that PQ912 could be effective in Huntington's disease in an animal model. Backup candidates are in pre-clinical stage: PBD-C06 (monoclonal antibody that targets pGlu-Abeta), and PQ1565 (small molecule QC enzyme inhibitor).

INDUSTRY OUTLOOK

There are 44m dementia sufferers worldwide, 60% of whom have AD. The lack of disease-modifying therapies leaves a vast unmet clinical need. This, combined with increasing understanding of the disease process and the development of biomarkers, has led to increased optimism that a disease-modifying therapy may be found.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(13.7)	(13.8)	(181.30)	N/A	N/A
2017	0.0	(9.9)	(9.0)	(96.67)	N/A	N/A
2018e	0.0	(7.8)	(7.8)	(94.91)	N/A	N/A
2019e	0.0	(7.9)	(7.9)	(96.64)	N/A	N/A

Sector: Pharma & healthcare

Price: €1.89
Market cap: €22m
Market Euronext Paris

Share price graph (€)



Company description

Quantum Genomics is a biopharmaceutical company developing QGC001, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment.

Price performance

%	1m	3m	12m
Actual	8.1	(5.4)	(38.2)
Relative*	9.6	(3.4)	(39.7)

* % Relative to local index

Analyst

Maxim Jacobs

Quantum Genomics (ALQGC)

INVESTMENT SUMMARY

Quantum Genomics is investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. Quantum Genomics recently announced that it has enrolled the NEW-HOPE trial faster than expected, with data to come around mid-November (previously around the end of Q119). NEW-HOPE is a study of fribastat in 256 hypertensive overweight patients across 25 major US hospitals, with a primary endpoint of change from baseline in office systolic blood pressure (SBP) at week eight. The company is also launching a Phase IIb in heart failure in Q418 with results expected in H220.

INDUSTRY OUTLOOK


The angiotensin pathway is one of the primary methods of modulating blood pressure and is the target of many anti-hypertensive drugs, including ACE's and ARB's. However, there is a parallel pathway in the brain responsible for the secretion of vasopressin and heart rate that is unaddressed by current drugs and that is being targeted by Quantum Genomics.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(6.2)	(6.2)	(59.79)	N/A	N/A
2017	0.0	(10.3)	(10.3)	(92.81)	N/A	N/A
2018e	0.0	(10.9)	(11.4)	(73.20)	N/A	N/A
2019e	0.0	(14.8)	(16.2)	(99.97)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$8.11
Market cap: US\$204m
Market: NASDAQ, TASE

Share price graph (US\$)



Company description

RedHill Biopharma is a specialty pharma company with a broad R&D pipeline focusing on gastrointestinal and inflammatory diseases and also promotes four GI products in the US. The most advanced programs are TALICIA (RHB-105) for H. pylori infection, RHB-104 for Crohn's disease and BEKINDA for gastroenteritis and IBS-D.

Price performance

%	1m	3m	12m
Actual	33.6	4.2	(5.4)
Relative*	29.8	(0.4)	(18.6)

* % Relative to local index

Analyst

Dr Jonas Pecilius

RedHill Biopharma (RDHL)

INVESTMENT SUMMARY

RedHill has a broad R&D pipeline, but is focusing on GI and inflammatory diseases. The most advanced assets are TALICIA (RHB-105) for H. pylori infection (top-line results from confirmatory Phase III expected before end of 2018); RHB-104 for Crohn's disease (positive top-line results from first Phase III announced July 2018); BEKINDA for both gastroenteritis (positive results from first Phase III announced June 2017) and IBS-D (positive final Phase II results announced January 2018); and RHB-204 for pulmonary non-tuberculous mycobacteria infections (pivotal Phase III trial to start Q119). RedHill promotes four GI products in the US (Donnatal, EnteraGam, Esomeprazole Strontium DR Capsules 49.3mg and Mytesi). Q218 net revenues were \$2.4m. RedHill recently uplisted to Nasdaq Global Market and on 14 August closed an offering of American depository shares, raising \$25m gross.

INDUSTRY OUTLOOK

RedHill's main focus on GI and inflammation include a range of conditions, which although can be treated with a variety of innovative and established products, there is still an unmet need in each of the diseases. In our view, carefully positioned, innovative solutions for the patients will attract attention.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.1	(30.5)	(29.4)	(22.85)	N/A	N/A
2017	4.0	(51.9)	(45.5)	(25.99)	N/A	N/A
2018e	16.6	(39.2)	(39.3)	(18.41)	N/A	N/A
2019e	30.2	(35.7)	(35.8)	(16.74)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.17
Market cap: A\$34m
Market: ASX

Share price graph (A\$)



Company description

Regeneus is a clinical-stage regenerative medicine company developing innovative cell-based therapies for the human & animal health markets.

Price performance

%	1m	3m	12m
Actual	(15.4)	37.5	37.5
Relative*	(14.0)	35.1	27.9

* % Relative to local index

Analyst

Dr Dennis Hulme

Regeneus (RGS)

INVESTMENT SUMMARY

Regeneus is developing its mesenchymal stem cell technology for musculoskeletal conditions in humans (Progenza) and animals (CryoShot). It has entered a collaboration with AGC for exclusive manufacture of Progenza cells for Japan. Regeneus and AGC have formed a 50:50 JV, which is seeking to sub-license partners to develop and commercialise Progenza in Japan in a number of indications; the first Progenza clinical development licence deal is expected by Q418. Japanese legislation offers an accelerated path to market for regenerative medicines. Progenza therapy reduced osteoarthritis knee pain in Phase I. Regeneus was granted a US patent in July covering the composition and use of Progenza. Its autologous cancer vaccine RGSH4K was safe and showed encouraging signs of immune stimulation and antitumour activity in a Phase I study. Its Sygenus topical secretions technology improved the appearance of acne in adults in a clinical study, and produced better pain relief than morphine in preclinical studies.

INDUSTRY OUTLOOK

Regeneus focuses on early-stage product development, then partners. In addition to the AGC deal for Progenza in Japan, it has partnered with a global animal health company for CryoShot Canine. It will seek to identify wider applications of Progenza, beyond arthritis.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	10.0	4.9	3.3	1.57	10.8	9.9
2018	0.6	(4.8)	(5.2)	(2.48)	N/A	N/A
2019e	7.8	2.3	2.2	1.04	16.3	15.4
2020e	1.6	(4.0)	(4.2)	(2.00)	N/A	N/A

Sector: Pharma & healthcare

Price: 85.0p
Market cap: £27m
Market: LSE

Share price graph (p)

Company description

ReNeuron is a UK biotech company developing allogeneic cell therapies: CTX neural stem cell products for stroke disability (Phase IIb) and human retinal progenitor cells for retinitis pigmentosa (Phase I/II).

Price performance

%	1m	3m	12m
Actual	(9.6)	21.4	(50.0)
Relative*	(5.7)	28.2	(49.8)

* % Relative to local index

Analyst

Andy Smith

ReNeuron Group (RENE)

INVESTMENT SUMMARY

ReNeuron is focused on three cell therapy-based programs. This includes the CTX neural stem cell program which demonstrated positive response rates in key measures were sustained after extended follow-up. ReNeuron will be moving forward with a Phase IIb in chronic stroke disability in FY18 with data expected around YE19. ReNeuron also has the hRPC (human retinal progenitor cells) program for retinitis pigmentosa (currently in Phase I/II) and will also be starting a Phase IIa trial in cone-rod dystrophy.

INDUSTRY OUTLOOK

Limited drug development has targeted chronic stroke to date, which is the area in which ReNeuron is attempting to demonstrate a meaningful reduction in disability. If shown, it would offer a compelling case for further development and/or partnering.

Y/E Mar	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2017	0.9	(19.8)	(18.2)	(0.49)	N/A	N/A
2018	0.9	(20.2)	(21.0)	(55.66)	N/A	N/A
2019e	3.9	(25.7)	(25.6)	(71.21)	N/A	N/A
2020e	1.0	(30.3)	(30.4)	(84.40)	N/A	N/A

Sector: Pharma & healthcare

Price: €16.40
Market cap: €820m
Market: Madrid Stock Exchange

Share price graph (€)

Company description

Laboratorios Farmacéuticos ROVI is a fully integrated Spanish speciality pharmaceutical company involved in the development, in-licensing, manufacture and marketing of small molecule and speciality biologic drugs with a particular expertise in low molecular weight heparin (LMWH).

Price performance

%	1m	3m	12m
Actual	1.2	2.2	2.5
Relative*	3.4	8.4	13.9

* % Relative to local index

Analyst

Dr Susie Jana

ROVI Laboratorios Farmaceuticos (ROVI)

INVESTMENT SUMMARY

ROVI, a profitable, speciality healthcare company, markets ~40 proprietary and in-licensed products across nine core franchises mainly in its domestic Spanish market. ROVI is at a major inflection point; it has launched its internally developed biosimilar enoxaparin into multiple European countries ahead of any competition; this is a key driver of sales and operating growth in the medium term. R&D progress continues with its proprietary ISM technology, notably with Risperidone ISM or DORIA, a long-acting injectable for schizophrenia, which is expected to read out data in Q219 from its Phase III PRISMA trial.

INDUSTRY OUTLOOK

ROVI has a strong presence in the Spanish heparin market (and select international markets through partners), where it has been manufacturing and marketing its flagship product Hibor (second-generation LMWH) since 1998.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	265.2	39.3	30.3	58.11	28.2	34.9
2017	275.6	30.5	20.3	39.99	41.0	28.3
2018e	293.6	26.4	16.4	31.43	52.2	17.8
2019e	314.9	37.5	27.0	51.63	31.8	45.6

Sector: Pharma & healthcare

Price: 52.00PLN
Market cap: PLN831m
Market: Warsaw Stock Exchange

Share price graph (PLN)

Company description

Selvita is an R&D and drug discovery services company. It operates two main business units: Innovations Platform (internal R&D pipeline) and Research Services (medicinal chemistry/biology, biochemistry).

Price performance

%	1m	3m	12m
Actual	(7.1)	(7.0)	7.8
Relative*	(6.0)	(6.8)	20.6

* % Relative to local index

Analyst

Dr Jonas Peciusis

Selvita (SLV)

INVESTMENT SUMMARY

Selvita is an R&D and drug discovery services company. Total sales in H118 were PLN 37.3m (an increase of 19% from H117) and most of the growth continues to come from the services segment. In R&D, Selvita out-licensed its lead drug SEL24's to Menarini in March 2017 with a total potential value of the deal of €89.1m. SEL24 is a dual PIM/FLT3 inhibitor in Phase I/II for AML and the first such compound to progress to Phase I/II, to our knowledge. Second lead product is SEL120, a CDK8 inhibitor, partnered with the Leukemia & Lymphoma Society for AML and is undergoing IND-enabling studies. Multiple collaborations signed with partners such as Merck KGaA, H3 Biomedicine (Eisai) and JV (Nodthera) with Epidarex Capital validate Selvita's research capabilities. Recently, Selvita completed a share issue raising PLN134m, which will be a part of the total funds of PLN390m the company expects to invest until 2021 significantly ramping up its R&D activities.

INDUSTRY OUTLOOK

The profiles of SEL24 and SEL120 are potentially unique when compared to existing clinical-stage competitors and both candidates may offer efficacy advantages. Contract research is a fiercely competitive, but still rapidly growing market and we believe Selvita's geographical location and lower cost benefits make it well placed to compete.

Y/E Dec	Revenue (PLNm)	EBITDA (PLNm)	PBT (PLNm)	EPS (gr)	P/E (x)	P/CF (x)
2016	66.7	8.3	4.6	63.82	81.5	N/A
2017	105.9	18.5	10.2	50.76	102.4	69.9
2018e	101.3	(0.4)	14.3	91.04	57.1	N/A
2019e	116.8	1.9	(4.5)	(26.23)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.94
Market cap: US\$70m
Market: NASDAQ

Share price graph (US\$)

Company description

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed SNS-062, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.

Price performance

%	1m	3m	12m
Actual	(15.3)	(13.8)	(15.3)
Relative*	(17.7)	(17.6)	(27.1)

* % Relative to local index

Analyst

Maxim Jacobs

Sunesis Pharmaceuticals (SNSS)

INVESTMENT SUMMARY

Sunesis is a pharmaceutical company developing small molecule oncology drugs. Its lead programme is SNS-062, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice-a-day dosing. The programme is entering a dose escalation Phase Ib/II trial. It has also developed TAK-580 with partner Takeda, and the preclinical PDK1 inhibitor SNS-510.

INDUSTRY OUTLOOK

Sunesis is an oncology company with an early stage asset with a validated target targeting patients that are in B-cell malignancies.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	2.5	(36.3)	(38.0)	(242.37)	N/A	N/A
2017	0.7	(34.4)	(35.5)	(144.63)	N/A	N/A
2018e	0.2	(30.3)	(31.9)	(88.71)	N/A	N/A
2019e	0.0	(31.2)	(36.3)	(96.54)	N/A	N/A

Sector: Pharma & healthcare

Price: ¥122.00
Market cap: ¥9107m
Market: Tokyo

Share price graph (¥)



Company description

SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio's branded formulation of bendamustine HCl. Rigosertib was in-licensed from Onconova.

Price performance

%	1m	3m	12m
Actual	5.2	(27.8)	(47.0)
Relative*	3.5	(24.0)	(49.2)

* % Relative to local index

Analyst

Dr Dennis Hulme

SymBio Pharmaceuticals (4582)

INVESTMENT SUMMARY

SymBio is a speciality pharma focused on Asia-Pacific markets, and has in-licensed two orphan blood cancer products. Treakisym i.v. was approved for r/r low grade NHL/MCL in 2010 and in 2016 received approvals in CLL and first-line low grade NHL/MCL; these new approvals saw in-market Treakisym sales increase by 22% in H1 2018, following 61% growth in 2017 (NHI price basis). In August 2017, SymBio initiated a Phase III trial in Japan of Treakisym in r/r diffuse large B-cell lymphoma, while in September 2017 it in-licensed liquid formulations for injection that will provide Treakisym with patent protection that extends to 2031. A Phase I trial of oral Treakisym commenced in January. Rigosertib i.v. is in development for r/r higher-risk myelodysplastic syndromes (HR-MDS) and is in a pivotal Phase III global study which has expanded from 225 to 360 patients in early 2018; SymBio is enrolling patients in Japan and is aiming for potential filing in 2021. SymBio intends to participate in a planned global trial of high-dose oral rigosertib in untreated HR-MDS.

INDUSTRY OUTLOOK

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operating leverage.

Y/E Dec	Revenue (¥m)	EBITDA (¥m)	PBT (¥m)	EPS (fd) (¥)	P/E (x)	P/CF (x)
2016	2368.0	(2101.0)	(2317.0)	(59.0)	N/A	315.7
2017	3444.0	(3917.0)	(3977.0)	(79.8)	N/A	496.7
2018e	4203.0	(3004.0)	(3030.0)	(54.2)	N/A	166.1
2019e	4325.0	(3591.0)	(3636.0)	(62.9)	N/A	403.2

Sector: Pharma & healthcare

Price: NOK10.98
Market cap: NOK578m
Market: Oslo

Share price graph (NOK)



Company description

Targovax is an immuno-oncology company headquartered in Oslo, Norway, with two technology platforms that are being developed in a number of oncological indications. ONCOS-102 is an oncolytic virus technology. TG is a therapeutic cancer vaccine platform comprising of peptides mimicking the most common RAS oncogenic mutations.

Price performance

%	1m	3m	12m
Actual	1.1	(15.0)	(41.3)
Relative*	0.4	(16.3)	(49.5)

* % Relative to local index

Analyst

Dr Jonas Peciulis

Targovax (TRVX)

INVESTMENT SUMMARY

Targovax is an immuno-oncology (IO) company specialising in two distinct, but complementary immune activator approaches. Targovax's core proposition is to use its products as immune response primers and combine with other anticancer therapies, such as checkpoint inhibitors, for increased efficacy. ONCOS-102 is a genetically engineered adenovirus being tested in advanced melanoma, mesothelioma, peritoneal malignancies and prostate cancer. One of the key catalysts this year is the Phase I melanoma trial with interim data due in H218. Targovax has also been developing two mutant RAS-specific neo-antigen vaccines from its TG platform for colorectal and pancreatic cancers. It recently announced a strategic decision to move away from developing TG01 for resected pancreatic cancer based on new data presented at ASCO, which suggested an almost two-year improvement in overall survival with FOLFIRINOX compared to gemcitabine.

INDUSTRY OUTLOOK

Checkpoint inhibitors (CPIs) gained popularity over the past several years, however, a large proportion of patients do not respond to CPIs. Both Targovax's platform technologies are designed to prime immune response to cancers, which offers synergies for use in combination with other immuno-oncology therapies.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2016	0.0	(119.2)	(122.7)	(354.65)	N/A	N/A
2017	0.0	(119.6)	(122.3)	(258.06)	N/A	N/A
2018e	0.0	(149.3)	(147.5)	(280.09)	N/A	N/A
2019e	0.0	(170.0)	(170.3)	(322.73)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.82
Market cap: A\$107m
Market: ASX

Share price graph (A\$)



Company description

Telix Pharmaceuticals is a Melbourne-headquartered global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly targeted radiation.

Price performance

%	1m	3m	12m
Actual	15.4	26.0	N/A
Relative*	17.3	23.8	N/A

* % Relative to local index

Analyst

Dr Dennis Hulme

Telix Pharmaceuticals (TLX)

INVESTMENT SUMMARY

Telix has assembled a portfolio of promising molecularly targeted radiation (MTR) therapeutic and imaging products for kidney, prostate and brain cancers; it strengthened its position in prostate cancer in September through the acquisition of Atlab. Each product has been validated by clinical studies or compassionate use, thus reducing development risk. The ZIRCON confirmatory Phase III study for kidney cancer imaging agent TLX250-CDx is expected to commence in Q418 at the completion of an ongoing bridging study, and report in H219. The IPAX-1 Phase I/II study of TLX101 therapy in GBM (brain cancer) is due to commence shortly and read out in H219. Preparations for multiple Phase I/II studies of other agents are also underway. It has begun commercialising an investigational prostate cancer imaging kit in the US, and is developing plans for a pivotal study to allow full approval.

INDUSTRY OUTLOOK

Big pharma has shown a keen interest in MTR products. In 2017 Novartis acquired Advanced Accelerator Applications, the developer of the MTR therapeutic Lutathera, for US\$3.9bn. In 2014 Bayer acquired Algeta for ~US\$2.6bn, Algeta had developed Xofigo, a therapeutic radiopharmaceutical for prostate cancer. Endocyte is using Telix's prostate cancer imaging kit to screen patients for its VISION Phase III trial.

Y/E Dec	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	N/A	N/A	N/A	N/A	N/A	N/A
2017	0.4	(6.4)	(6.4)	(4.98)	N/A	N/A
2018e	5.0	(13.0)	(12.7)	(6.12)	N/A	N/A
2019e	8.4	(17.9)	(17.7)	(8.13)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$3.89
Market cap: US\$4m
Market: NASDAQ, TASE

Share price graph (US\$)



Company description

Therapix Biosciences is an Israeli pharmaceutical company developing two cannabinoids to treat Tourette syndrome and mild cognitive impairment. It is currently in Phase IIa and soon to begin Phase I, respectively, and owns or licenses several IPs for cannabinoid nasal and sublingual administration.

Price performance

%	1m	3m	12m
Actual	3.7	(17.2)	(29.4)
Relative*	0.8	(20.9)	(39.3)

* % Relative to local index

Analyst

Maxim Jacobs

Therapix Biosciences (TRPX)

INVESTMENT SUMMARY

Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. Therapix recently announced the results of its Phase IIa study of THX-110 for the treatment of Tourette syndrome (TS). The study showed a statistically significant ($p=0.002$) reduction in tic severity of 21%. The company has also initiated a Phase IIa for obstructive sleep apnea (OSA) and is beginning a Phase IIa for low back pain. In July, the company announced that it had signed a term sheet with CURE Pharmaceutical in which CURE would acquire the non-pain assets of Therapix in exchange for stock. Once the deal closes, Therapix will become a significant shareholder in CURE.

INDUSTRY OUTLOOK

Diseases of the brain are a major unmet medical need with few effective or approved therapies for a host of diseases. Cannabinoids have had promising data in many indications in the area and is a class that has received a lot of interest.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	N/A	N/A	N/A	N/A	N/A	N/A
2016	0.0	(1.7)	(1.7)	(179.9)	N/A	N/A
2017e	0.0	(4.0)	(4.3)	(118.4)	N/A	N/A
2018e	0.0	(7.7)	(7.7)	(200.1)	N/A	N/A

Sector: Pharma & healthcare

Price: €3.12
Market cap: €194m
Market: Euronext Paris

Share price graph (€)

Company description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

Price performance

%	1m	3m	12m
Actual	1.5	(3.7)	(11.8)
Relative*	2.8	(1.7)	(14.0)

* % Relative to local index

Analyst

Dr Daniel Wilkinson

Transgene (TNG)

INVESTMENT SUMMARY

Transgene is focused on the development of its cancer immunotherapy products in combination with immune checkpoint inhibitors (ICIs) and infectious disease programmes. The company is running 11 clinical trials, including a Phase 2 TG4010 combination trial with Opdivo and chemotherapy in 1L NSCLC, a Phase 2 trial testing TG4010+Opdivo in 2L NSCLC, a Phase 2 with Pexa-Vec+Opdivo in 1L advanced liver cancer, a Phase 1b/2 trial of TG4001 in HPV positive cancers in combination with avelumab, a Phase 1 trial with Pexa-Vec+Yervoy in solid tumours and a Phase 1/2 of Pexa-Vec+metronomic cyclophosphamide in HER2 negative breast cancer. Transgene and partner Sillajen are running a global 600-patient Phase 3 study in liver cancer. Transgene recently announced a strategic agreement with Tasly Biopharmaceuticals for full Greater China rights to T601 and T101 (Transgene received \$48m in Tasly shares). Gross cash at 31 March 2017 was €35.6m.

INDUSTRY OUTLOOK

Immunotherapies are among the most promising class of products for cancer. Increased attention is now being paid to the use of combination therapy approaches to improve cancer response rates further.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	10.3	(20.4)	(23.1)	(42.9)	N/A	N/A
2017	8.1	(26.4)	(35.0)	(52.0)	N/A	N/A
2018e	7.2	(28.4)	(36.8)	(50.6)	N/A	N/A
2019e	7.9	(31.1)	(34.0)	(54.8)	N/A	N/A

Sector: Pharma & healthcare

Price: €2.45
Market cap: €57m
Market: Euronext Paris

Share price graph (€)

Company description

TxCell is developing regulatory T-cell therapies against autoimmune and inflammatory disorders. It uses a novel CAR Treg technology platform. In H1 2019, TxCell plans to file for approval to start a transplant clinical study.

Price performance

%	1m	3m	12m
Actual	0.8	166.6	45.0
Relative*	2.2	172.3	41.3

* % Relative to local index

Analyst

Dr John Savin

TxCell (TXCL)

INVESTMENT SUMMARY

TxCell is in the process of being acquired by the leading US biotech company Sangamo for €2.58/share. Sangamo intends to evaluate the potential of CAR-Treg therapies to prevent graft rejection in solid organ transplant and for the treatment of autoimmune diseases like Crohn's disease and multiple sclerosis. The proposed acquisition of TxCell could accelerate CAR-Treg into the clinic. In 2019, Sangamo expects to submit a clinical trial authorisation application in Europe for the first CAR-Treg product candidate for solid organ transplant, and to initiate a Phase I/II clinical trial later in 2019. Sangamo intends to use its zinc finger nuclease (ZFN) gene editing technology to develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune diseases.

INDUSTRY OUTLOOK

TxCell is focused on CAR Treg development using humanised chimeric antigen receptor (CAR) technology similar to that in CAR T-cell cancer therapy. A granted European patent offers broad protection.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(11.9)	(12.7)	(97.5)	N/A	N/A
2017	0.0	(9.3)	(9.7)	(46.3)	N/A	N/A
2018e	0.0	(11.8)	(11.9)	(53.0)	N/A	N/A
2019e	0.0	(11.9)	(12.0)	(53.7)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$2.25
Market cap: US\$68m
Market: NYSE MKT

Share price graph (US\$)

Company description

VolitionRx is a Belgium-based diagnostics company focused on developing blood-based cancer diagnostics based on its proprietary Nu.Q™ technology. Its lead program is in colorectal cancer, which entered the European market in 2017.

Price performance

%	1m	3m	12m
Actual	17.8	(6.3)	(18.8)
Relative*	14.5	(10.4)	(30.1)

* % Relative to local index

Analyst

Dr Jonas Peciulis

VolitionRx (VNRX)

INVESTMENT SUMMARY

VolitionRx's proprietary Nu.Q™ technology detects the level and structure of nucleosomes in the blood using one drop of blood serum. It is currently focused on colorectal cancer (CRC), a very large opportunity with around 225 million people eligible for screening (US/EU). VolitionRx will be participating in a 13,500 undiagnosed person trial in the US to gain FDA approval for front-line CRC screening. For Europe, the company plans to market a triage screening test followed by a front-line screening test. Readouts from 4,300 and 12,000+ sample studies are expected in H218 and Q119 respectively to support a CE Mark. Volition recently announced positive data from a pancreatic cancer study with Nu.Q™. Volition also recently secured new funding: \$9m private placement, \$8.4m (gross) through a registered public offering of common shares and \$700k from the Walloon Regional Government. Volition's new partner Active Motif will begin to sell Nu.Q™ assay research kits which Volition hope will help to validate the assays and explore new indications.

INDUSTRY OUTLOOK

The blood-based cancer screening market is in its nascent stages with great potential and serves an unmet medical need. Currently there are few, if any, non-invasive screening methods for the vast majority of cancers.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(12.4)	(12.5)	(54.02)	N/A	N/A
2017	0.0	(15.0)	(15.1)	(57.29)	N/A	N/A
2018e	0.1	(16.9)	(17.0)	(54.33)	N/A	N/A
2019e	1.4	(17.2)	(17.3)	(53.40)	N/A	N/A

Company coverage

Company	Note	Date published
4SC	Update; Update	03/05/2018; 17/08/2018
Acacia Pharma	Initiation	07/09/2018
Acarix	Update; Update	30/05/2018; 17/09/2018
AFT Pharmaceuticals	Update; Update	28/03/2018; 30/05/2018
Allium Medical	Outlook; Update	17/07/2018; 20/08/2018
Angle	Flash; Flash	16/06/2017; 05/07/2017
ASIT biotech	Initiation; Update	29/05/2018; 16/07/2018
ASLAN Pharmaceuticals	Update; Update	09/07/2018; 19/09/2018
Atossa Genetics	Update; Update	26/04/2018; 15/06/2018
Basilea Pharmaceutica	Outlook; Update	16/07/2018; 21/08/2018
Bio-Light Life Sciences	Update; Update	24/04/2018; 09/07/2018
Bionomics	Update; Update	18/07/2018; 24/08/2018
BioPorto Diagnostics	Initiation	22/08/2018
BONESUPPORT	Initiation; Update	21/06/2018; 03/08/2018
Cantargia	Initiation; Update	07/06/2018; 13/09/2018
Carmat	Outlook; Update	31/07/2017; 21/12/2017
Cellular Biomedicine Group	Initiation; Update	02/10/2017; 04/04/2018
Celyad	Update; Update	21/06/2018; 02/08/2018
Clal Biotechnology Industries	Update; Update	06/06/2018; 23/08/2018
Collplant Holdings	Update; Update	28/03/2018; 30/05/2018
Deinove	Outlook; Update	01/09/2017; 23/10/2017
Destiny Pharma	Initiation	04/09/2018
e-Therapeutics	Update; Update	05/01/2018; 23/04/2018
Elbit Medical Technologies	Initiation; Update	28/06/2018; 06/09/2018
Hutchison China Meditech	Update; Update	20/08/2018; 18/09/2018
Hybrigenics	Outlook; Update	31/01/2018; 24/05/2018
Immunicum	Initiation	07/06/2018
Immunovia	Outlook; Update	22/03/2018; 06/09/2018
Immutep	Outlook; ADR Outlook	30/08/2018; 30/08/2018
InMed Pharmaceuticals	Initiation; Update	07/06/2018; 20/09/2018
Intec Pharma	Update; Update	21/05/2018; 23/07/2018
International Stem Cell	Update; Update	06/06/2018; 20/08/2018
Kazia Therapeutics	ADR Update; Update	19/09/2018; 19/09/2018
Kiadis Pharma	Update; Update	08/12/2016; 06/01/2017
MagForce	Update; Update	18/05/2018; 04/07/2018
Medigene	Update; Update	17/05/2018; 07/08/2018
Mesoblast	Update; Update	07/06/2017; 07/11/2017
Mologen	Update; Update	10/11/2017; 29/05/2018
NetScientific	Update; Update	12/01/2018; 18/04/2018
NeuroVive Pharmaceutical	Update; Update	05/03/2018; 04/06/2018
Newron Pharmaceuticals	Outlook; Update	13/10/2017; 04/04/2018
Nuevolution	Update; Outlook	24/11/2017; 15/03/2018
Oncology Venture	Update; Update	02/07/2018; 13/09/2018
Onxeo	Outlook; Update	29/11/2017; 27/04/2018
Orexo	Update; Outlook	13/07/2018; 13/09/2018
Oryzon Genomics	Update; Outlook	22/05/2018; 18/07/2018

Oxford BioMedica	Outlook; Update	10/05/2018; 08/06/2018
Pacific Edge	Outlook; Update	09/01/2018; 04/06/2018
Paion	Outlook; Update	14/05/2018; 13/08/2018
PDL BioPharma	Update; Update	22/05/2018; 16/08/2018
PharmaMar	Update; Update	23/01/2018; 14/03/2018
Photocure	Update; Update	04/06/2018; 16/08/2018
Pixium Vision	Outlook; Update	08/03/2018; 09/08/2018
Pluristem Therapeutics	Update; Update	28/02/2018; 29/05/2018
Probiodrug	Update; Update	18/09/2017; 13/04/2018
Quantum Genomics	Outlook; Update	13/07/2018; 10/09/2018
Redhill Biopharma	Update; Update	24/05/2018; 08/08/2018
Regeneus	Outlook; Update	29/04/2018; 04/09/2018
ReNeuron Group	Update; Flash	13/07/2018; 20/07/2018
ROVI Laboratorios Farmaceuticos	Flash; Update	10/05/2018; 30/07/2018
Selvita	Update; Update	16/04/2018; 29/06/2018
Sunesis Pharmaceuticals	Update; Update	18/05/2018; 17/08/2018
SymBio Pharmaceuticals	Outlook; ADR Outlook	06/04/2018; 09/04/2018
Targovax	Update; Update	16/03/2018; 13/06/2018
Telix Pharmaceuticals	Initiation	20/08/2018
Therapix Biosciences	Update; Update	18/08/2017; 17/11/2017
Transgene	Update; Outlook	23/03/2018; 16/07/2018
TxCell	Outlook; Update	22/02/2018; 12/06/2018
VolitionRx	Update; Update	13/03/2018; 18/07/2018

Investment companies[BB Biotech AG](#)

Investment trust review

09/02/2016; 27/02/2017

[Biotech Growth Trust \(The\)](#)

Investment trust review

20/07/2016; 21/02/2017

[International Biotechnology Trust](#)

Investment trust review

03/03/2015; 11/12/2015

QuickViews

To view the QuickViews we publish see the [healthcare](#) sector profile page on our website.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investments Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Frankfurt +49 (0)69 78 8076 960
Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
295 Madison Avenue, 18th Floor
10017, New York
US

Sydney +61 (0)2 8249 8342
Level 4, Office 1205
95 Pitt Street, Sydney
NSW 2000, Australia